

#IFW

PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/810,020
	Filing Date	03/26/2004
	First Named Inventor	Lin, Henry C.
	Art Unit	1645
	Examiner Name	Swartz, Rodney P.
Total Number of Pages in This Submission	Attorney Docket Number	04-11US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached \$65	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Request to Correct Priority Claim	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Declaration and Power of Attorney, Declaration, 2 pages	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Information Disclosure Statement
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Reference List: Form 1449 (41 pages)
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Nasotech Pharmaceutical Company Inc., Peter J. Knudsen, Attorney, Registration No. 40682
Signature	
Date	October 31, 2005

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being submitted to the United States Postal Service, Priority Mail (2 boxes), to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Jeffrey L. Granger		
Signature		Date	October 31, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (12-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/8/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL For FY 2005		Complete if Known	
		Application Number	10/810,020
		Filing Date	3/26/2004
		First Named Inventor	Lin
		Examiner Name	Swartz, Rodney P.
<input type="checkbox"/> Applicant Claims small entity status. See 37 CFR 1.27	Art Unit	1645	
TOTAL AMOUNT OF PAYMENT	(\$) 180.00	Attorney Docket No.	04-11US

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 502769 Deposit Account Name: Natestch Pharmaceutical Company Inc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below☐ Charges fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	0.00
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Small Entity Fee (\$)	Small Entity Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180
Total Claims	Extra Claims	Fee (\$)
- 20 or HP = 0	x	\$50.00
HP = highest number of total claims paid for, if greater than 20	=	\$ 0.00
Indep. Claims	Extra Claims	Fee (\$)
- 3 or HP = 0	x	\$200.00
HP = highest number of independent claims paid for, if greater than 3	=	\$ 0.00

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41 (a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number)	x	=

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Submission of Information Disclosure Statement under 37 C.F.R. 1.17(p)

Fees Paid(\$)

180.00

SUBMITTED BY

Signature	Registration No. 40682 (Attorney/Agent)	Telephone 425-908-3643
Name (Print/Type) Peter J. Knudsen		Date October 31, 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Henry C. Lin

U.S. Patent Application Serial No.:
10/810,020

Filed: 3/26/2004

Title: METHODS FOR MANIPULATING
UPPER GASTROINTESTINAL
TRANSIT, BLOOD FLOW, AND
SATIETY, AND FOR TREATING
VISCERAL HYPERALGESIA

Examiner Name: Swartz, Rodney P.

Group Art Unit: 1645

Attorney Docket No.: 04-11US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of international application; or **before mailing date of first office action** on the merits; whichever occurs last)

☒ under 37 CFR 1.97(c) together with either a:
☐ Statement under 37 CFR 1.97(e), or
☒ a \$180.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)


☐ under 37 CFR 1.97(d) together with a:
☐ Statement under 37 CFR 1.97(e), and
☐ a \$180.00 fee set forth in 37 CFR 1.17(p).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☒ Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.


Respectfully submitted,



Peter J. Knudsen
Attorney/Agent for Applicant(s)
Reg. No. 40682

Date: October 31, 2005

Telephone No.: (425) 908-3643
Facsimile No. (425) 908-3653



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	1	of	41	Attorney Docket Number	04-11US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-4,002,531	Issued 1/11/1977	Pierce Chemical Company	
		US-5,122,614	Issued 6/16/1992	Enzon, Inc.	
		US-5,284,839	Issued 2/08/1994	Perstorp, AB	
		US-5,349,052	Issued 9/20/1994	Royal Free Hospital School of Medicine	
		US-5,428,128	Issued 6/27/1995	Mensi-Fattohi, N. et al.	
		US-5,643,575	Issued 7/01/1997	Enzon, Inc.	
		US-5,880,131	Issued 3/09/1999	Enzon, Inc.	
		US-5,936,092	Issued 10/10/1999	The University of Southern California	
		US-6,093,692	Issued 7/25/2000	The University of Southern California	
		US-6,127,355	Issued 10/03/2000	Enzon, Inc.	
		US-6,225,445	Issued 5/01/2001	The University of Southern California	
		US-6,355,478	Issued 3/12/2002	Eli Lilly and Company	
		US-6,410,707	Issued 6/25/2002	BioNebraska, Inc.	
		US-6,420,532	Issued 7/16/2002	Synaptic Pharmaceutical Corporation	
		US-6,447,743	Issued 10/10/2002	Atofina	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		PCT WO 93/19175 A1	9-30-1993	Novo Nordisk		
		PCT WO 95/06058 A1	3-02-1995	Royal Free Hospital School of Medicine		
		PCT WO 98/32466 A1	7-30-1998	Polymasc Pharmaceuticals PLC		
		PCT WO 96/22783	8-01-1996	North Carolina State University		
		PCT WO 99/43707 A1	9-02-1999	Novo Nordisk		
		PCT WO 00/34236 A1	6-15-2000	University of Southern California		
		PCT WO 00/42026 A1	7-20-2000	Novo Nordisk		
		PCT WO 00/68197	11-16-2000	Ortho-McNeil Pharmaceutical, Inc.		
		PCT WO 00/59887 A1	10-12-2000	Neurogen Corporation		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	2	of	41	Attorney Docket Number	04-11US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-4,160,452	07-1979	Theeuwes	
		US-4,183,960	01-1980	Asher et al.	
		US-4,193,985	03-1980	Bechgaard et al.	
		US-4,256,108	03-1981	Theeuwes	
		US-4,265,874	05-1981	Bonsen et al.	
		US-4,530,838	07-1985	Evans et al.	
		US-4,572,833	02-1986	Pedersen et al.	
		US-4,673,680	07/1987	Pendleton	
		US-4,690,822	09-1987	Uemura et al.	
		US-4,863,744	09-1989	Urguhart et al.	
		US-4,970,207	11-1990	Sato et al.	
		US-4,987,136	01-1991	Kreek et al.	
		US-4,990,617	02-1991	Boswell et al.	
		US-5,041,431	08-1991	Halskov	
		US-5,120,306	06-1992	Gosselin	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		PCT WO 00/78333 A2	12-28-2000	Eli Lilly and Company		
		PCT WO 01/04156 A1	1-18-2001	Zealand Pharmaceuticals A/S		
		PCT WO 01/14368 A1	3-01-2001	Viropharma Incorporated		
		PCT WO 01/14386 A1	3-01-2001	Banyu Pharmaceutical Co., Ltd.		
		PCT WO 01/35988 A1	5-25-2001	Novo Nordisk A/S		
		PCT WO 01/51078 A1	7-19-2001	Amylin Pharmaceuticals, Inc.		
		PCT WO 01/66135 A1	9-13-2001	Novo Nordisk A/S		
		PCT WO 01/76631 A2	10-18-2001	Cedars-Sinai Medical Center		
		PCT WO 01/89554 A2	11-29-2001	BioNebraska, Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	3	of	41	Attorney Docket Number	04-11US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,219,871	06-1993	Cross et al.	
		US-5,225,352	07-1993	Zanetta et al.	
		US-5,236,901	08-1993	Burks et al.	
		US-5,322,697	06-1994	Meyer	
		US-5,354,757	10-1994	Flynn et al.	
		US-5,362,756	11-1994	Riviere et al.	
		US-5,380,522	01-1995	Day	
		US-5,411,751	05-1995	Crissinger et al.	
		US-5,426,028	06-1995	Levy et al.	
		US-5,434,174	07-1995	Gidda et al.	
		US-5,443,826	08-1995	Borody	
		US-5,453,428	09-1995	Kaminski	
		US-5,519,014	05-1996	Borody	
		US-5,538,856	07-1996	Levy et al.	
		US-5,547,961	08-1996	Ohta et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		PCT WO 02/03978 A2	1-17-2002	Metabasis Therapeutics, Inc.; Sankyo Company Limited		
		PCT WO 02/066479 A1	8-29-2002	Banyu Pharmaceutical Co., Inc.		
		PCT WO 02/067918 A1	9-06-2002	Banyu Pharmaceutical Co., Inc.		
		EP 0 401 384 A1	12-12-1990	Kirin-Amgen, Inc.		
		EP 0 955 314 A2	11-10-1999	Adir et Compagnie		
		JP 60007934	1985			
		EP 0 200 902 A3	11-1986			
		EP 0 349 949	07-1989			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	4	of	41	Attorney Docket Number	04-11US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-5,550,132	08-1996	Benson et al.	
		US-5,589,168	12-1996	Allen et al.	
		US-5,599,795	02-1997	McCann et al.	
		US-5,612,366	03-1997	Becker et al.	
		US-5,627,200	05-1997	Kreutter et al.	
		US-5,645,997	07-1997	Kline et al.	
		US-5,648,355	07-1997	Theoharides	
		US-5,648,359	07-1997	Ohashi et al.	
		US-5,660,828	08-1997	Rodriguez et al.	
		US-5,668,143	09-1997	Ku et al.	
		US-5,677,326	10-1997	Tsuchiya et al.	
		US-5,679,684	10-1997	Benson et al.	
		US-5,684,017	11-1997	Harrison et al.	
		US-5,691,343	11-1997	Sandbom et al.	
		US-5,703,100	12-1997	McDonald et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		EP 0 539 319 A2	04-1993			
		WO 94/03380	03-1994			
		WO 96/18374	11-1996			
		WO 98/46997	10-1998			
		WO 98/56397	12-1998			
		FR 2 769 915	04-1999			
		WO 85/02840	07-1999			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
				Attorney Docket Number	04-11US
Sheet	5	of	41		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,707,642	01-1998	Yue	
		US-5,726,187	03-1998	Gaster et al.	
		US-5,728,380	03-1998	Allen et al.	
		US-5,736,560	04-1998	Cosford et al.	
		US-5,753,218	05-1998	Smith et al.	
		US-5,753,253	05-1998	Meyer	
		US-5,759,546	06-1998	Weinberg et al.	
		US-5,776,524	07-1998	Reinhart	
		US-5,780,026	07-1998	Yoshii et al.	
		US-5,821,259	10-1998	Theoharides	
		US-5,830,668	11-1998	Mordechai et al.	
		US-5,833,987	11-1998	Noelle et al.	
		US-5,834,215	11-1998	Garry et al.	
		US-5,846,933	12-1998	Korngold et al.	
		US-5,849,708	12-1998	Maratos-Flier	

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	7	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ABUCHOWSKI, A.; KAZO, G. M.; VERHOEST, C. R., JR.; VAN, ES T.; KAFKEWITZ, D.; NUCCI, M. L.; VIAU, A. T.; and DAVIS, F. F.; "Cancer Therapy With Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates;" <i>Cancer Biochem. Biophys.</i> ; June 1984; 7 (2); 175-186	
		BARLOW, S. E. and DIETZ, W. H.; "Obesity Evaluation and Treatment: Expert Committee Recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services;" <i>Pediatrics</i> ; September 1998; 102 (3); E29-	
		CALICETI, P.; SCHIAVON, O.; and VERONESE, F. M.; "Biopharmaceutical Properties of Uricase Conjugated to Neutral and Amphiphilic Polymers;" <i>Bioconjug. Chem.</i> ; July 1999; 10 (4); 638-646	
		CHELIKANI, P. K.; HAVER, A. C.; and REIDELBERGER, R. D.; "Intravenous Infusion of Peptide YY(3-36) Potently Inhibits Food Intake in Rats;" <i>Endocrinology</i> ; February 2005; 146 (2); 879-888	
		CLAPHAM, J.C.; ARCH, J.R.S.; TADAYYON, M.; "Anti-obesity drugs: a critical review of current therapies and future opportunities;" <i>Pharmacology and Therapeutics</i> ; 2001; vol. 89; 81-121	
		COX, J. E. and RANDICH, A.; "Enhancement of Feeding Suppression by PYY(3-36) in Rats With Area Postrema Ablations 1;" <i>Peptides</i> ; June 2004; 25 (6); 985-989	
		DELGADO, C.; FRANCIS, G. E.; and FISHER, D.; "The Uses and Properties of PEG-Linked Proteins;" <i>Crit Rev. Ther. Drug Carrier Syst.</i> ; 1992; 9 (3-4); 249-304	
		DREBORG, S. and AKERBLOM, E. B.; "Immunotherapy With Monomethoxypolyethylene Glycol Modified Allergens;" <i>Crit Rev. Ther. Drug Carrier Syst.</i> ; 1990; 6 (4); 315-365	
		ENG, J.; KLEINMAN, W. A.; SINGH, L.; SINGH, G.; and RAUFMAN, J. P.; "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, From Heloderma Suspectum Venom. Further Evidence for an Exendin Receptor on Dispersed Acini From Guinea Pig Pancreas;" <i>J. Biol. Chem.</i> ; April 1992; 267 (11); 7402-7405	
		FRANCIS, G. E.; FISHER, D.; DELGADO, C.; MALIK, F.; GARDINER, A.; and NEALE, D.; "PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: the Importance of Biological Optimisation of Coupling Techniques;" <i>Int. J. Hematol.</i> ; July 1998; 68 (1); 1-18	
		JÉQUIER, E.; "Energy, obesity and body weight standards;" <i>Am. J. Clin. Nutr.</i> ; 1987; 45; 1035-1047	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/810,020
			<i>Filing Date</i>	3/26/2004
			<i>First Named Inventor</i>	Lin
			<i>Art Unit</i>	1645
			<i>Examiner Name</i>	Swartz, Rodney P.
(Use as many sheets as necessary)			<i>Attorney Docket Number</i>	04-11US
Sheet	8	of	41	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KENCHIAIAH, S.; EVANS, J. C.; LEVY, D.; WILSON, P. W.; BENJAMIN, E. J.; LARSON, M. G.; KANNEL, W. B.; and VASAN, R. S.; "Obesity and the Risk of Heart Failure;" <i>N. Engl. J. Med.</i> ; August 2002; 347 (5); 305-313	
		KOPELMAN, P. G.; "Obesity As a Medical Problem;" <i>Nature</i> ; April 2000; 404 (6778); 635-643	
		LANGER, R.; "New Methods of Drug Delivery;" <i>Science</i> ; September 1990; 249 (4976); 1527-1533	
		MALIK, F.; DELGADO, C.; KNUSLI, C.; IRVINE, A. E.; FISHER, D.; and FRANCIS, G. E.; "Polyethylene Glycol (PEG)-Modified Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Conserved Biological Activity;" <i>Exp. Hematol.</i> ; September 1992; 20 (8); 1028-1035	
		MASSIE, B. M.; "Obesity and Heart Failure—Risk Factor or Mechanism?;" <i>N. Engl. J. Med.</i> ; August 2002; 347 (5); 358-359	
		MCGOWAN, B. and BLOOM, S.; "Peptide YY and Appetite Control 1;" <i>Curr. Opin. Pharmacol.</i> ; December 2004; 4 (6); 583-588	
		MORAN, TIMOTHY H.; SMEDH, ULRICA; KINZIG, KIMBERLY P.; SCOTT, KAREN A.; KNIPP, SUSAN; and LADENHEIM, ELLEN E.; "Peptide YY (3-36) Inhibits Gastric Emptying and Produces Acute Reductions in Food Intake in Rhesus Monkeys;" <i>AJP - Regulatory, Integrative and Comparative Physiology</i> ; September 2004; 00535-	
		MORPURGO, M.; SCHIAVON, O.; CALICETI, P.; and VERONESE, F. M.; "Covalent Modification of Mushroom Tyrosinase With Different Amphiphilic Polymers for Pharmaceutical and Biocatalysis Applications;" <i>Appl. Biochem. Biotechnol.</i> ; January 1996; 56 (1); 59-72	
		PITTMER, R. A.; MOORE, C. X.; BHAVSAR, S. P.; GEDULIN, B. R.; SMITH, P. A.; JODKA, C. M.; PARKES, D. G.; PATERNITI, J. R.; SRIVASTAVA, V. P.; and YOUNG, A. A.; "Effects of PYY[3-36] in Rodent Models of Diabetes and Obesity 1;" <i>Int. J. Obes. Relat Metab Disord.</i> ; August 2004; 28 (8); 963-971	
		RISSANEN, A.; HELIOVAARA, M.; KNEKT, P.; REUNANEN, A.; AROMAA, A.; and MAATELA, J.; "Risk of Disability and Mortality Due to Overweight in a Finnish Population;" <i>BMJ</i> ; October 1990; 301 (6756); 835-837	
		ROSSI, M. and BLOOM, S.R.; "Central Nervous System Neuropeptides Involved in Obesity;" <i>Handbook of Experimental Pharmacology</i> ; 149; 313-341	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/810,020
		<i>Filing Date</i>	3/26/2004
		<i>First Named Inventor</i>	Lin
		<i>Art Unit</i>	1645
		<i>Examiner Name</i>	Swartz, Rodney P.
(Use as many sheets as necessary)		<i>Attorney Docket Number</i>	04-11US
Sheet	9	of	41

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SCHUTZ, Y.; BESSARD, T.; and JEQUIER, E.; "Exercise and Postprandial Thermogenesis in Obese Women Before and After Weight Loss;" <i>Am. J. Clin. Nutr.</i> ; June 1987; 45 (6); 1424-1432	
		VERMA, I. M.; DESCHAMPS, J.; VAN, BEVEREN C.; and SASSONE-CORSI, P.; "Human Fos Gene;" <i>Cold Spring Harb. Symp. Quant. Biol.</i> ; 1986; 51 Pt 2 949-958	
		VOROBJEV, P. E.; ZARYTOVA, V. F.; and BONORA, G. M.; "Oligonucleotide Conjugated to Linear and Branched High Molecular Weight Polyethylene Glycol As Substrates for RNase H;" <i>Nucleosides Nucleotides</i> ; November 1999; 18 (11-12); 2745-2750	
		WALKER, M. W.; EWALD, D. A.; PERNEY, T. M.; and MILLER, R. J.; "Neuropeptide Y Modulates Neurotransmitter Release and Ca ²⁺ Currents in Rat Sensory Neurons;" <i>J. Neurosci.</i> ; July 1988; 8 (7); 2438-2446	
		WANG, Y.J. and HANSON, M.A.; "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers;" <i>J. Paren. Sci. & Tech.</i> ; 1988; 42; S1-S24	
		CASAFONT MORENCOS, F.; DE LAS HERAS CASTANO, G.; MARTIN RAMOS, L.; LOPEZ ARIAS, M. J.; LEDESMA, F.; and Pons Romero, F.; "Small Bowel Bacterial Overgrowth in Patients With Alcoholic Cirrhosis;" <i>Digestive Diseases and Sciences</i> ; June 1995; 40 (6); 1252-1256	
		ALANDER, M.; DE, SMET, I.; NOLLET, L.; VERSTRAETE, W.; VON, WRIGHT A.; and MATTILA-SANDHOLM, T.; "The Effect of Probiotic Strains on the Microbiota of the Simulator of the Human Intestinal Microbial Ecosystem (SHIME);" <i>Int. J Food Microbiol.</i> ; January 1999; 46 (1); 71-79; Abstract Only	
		ALBANO, S.A. et al; "Small Intestinal Bacterial Overgrowth in Systemic Lupus Erythematosus (SLE);" <i>Arthritis & Rheumatism</i> ; November 1999; 42(9 Suppl.); S305; Abstract 1409a	
		ALPERT, J. E.; MADDOCKS, A.; NIERENBERG, A. A.; O'SULLIVAN, R.; PAVA, J. A.; WORTHINGTON, J. J., III; BIEDERMAN, J.; ROSENBAUM, J. F.; and FAVA, M.; "Attention Deficit Hyperactivity Disorder in Childhood Among Adults With Major Depression;" <i>Psychiatry Res.</i> ; June 1996; 62 (3); 213-219; Abstract Only	
		ANDERSON, B. W.; KNEIP, J. M.; LEVINE, A. S.; and LEVITT, M. D.; "Influence of Infusate Viscosity on Intestinal Absorption in the Rat. An Explanation of Previous Discrepant Results;" <i>Gastroenterology</i> ; October 1989; 97 (4); 938-943	
		ANNESE, V.; BASSOTTI, G.; NAPOLITANO, G.; USAI, P.; ANDRIULLI, A.; and VANTRAPPEN, G.; "Gastrointestinal Motility Disorders in Patients With Inactive Crohn's Disease;" <i>Scand. J Gastroenterol.</i> ; November 1997; 32 (11); 1107-1117; Abstract Only	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/810,020
			<i>Filing Date</i>	3/26/2004
			<i>First Named Inventor</i>	Lin
			<i>Art Unit</i>	1645
			<i>Examiner Name</i>	Swartz, Rodney P.
(Use as many sheets as necessary)			<i>Attorney Docket Number</i>	04-11US
Sheet	10	of	41	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ASARIAN, L.; CORP, E. S.; HRUPKA, B.; and GEARY, N.: "Intracerebroventricular Glucagon-Like Peptide-1 (7-36) Amide Inhibits Sham Feeding in Rats Without Eliciting Satiety;" <i>Physiol Behav.</i> ; June 1998; 64 (3); 367-372; Abstract Only	
		AUTSCHBACH, F.; BRAUNSTEIN, J.; HELMKE, B.; ZUNA, I.; SCHURMANN, G.; NIEMIR, Z. I.; WALLICH, R.; OTTO, H. F.; and MEUER, S. C.; "In Situ Expression of Interleukin-10 in Noninflamed Human Gut and in Inflammatory Bowel Disease;" <i>Am J Pathol.</i> ; July 1998; 153 (1); 121-130; Abstract Only	
		BABYATSKY, M. W.; ROSSITER, G.; and PODOLSKY, D. K.; "Expression of Transforming Growth Factors Alpha and Beta in Colonic Mucosa in Inflammatory Bowel Disease;" <i>Gastroenterology</i> ; April 1996; 110 (4); 975-984; Abstract Only	
		BAGNOL, D.; MANSOUR, A.; AKIL, H.; and WATSON, S. J.; "Cellular Localization and Distribution of the Cloned Mu and Kappa Opioid Receptors in Rat Gastrointestinal Tract;" <i>Neuroscience</i> ; November 1997; 81 (2); 579-591; Abstract Only	
		BARNES, R. M.; ALLAN, S.; TAYLOR-ROBINSON, C. H.; FINN, R.; and JOHNSON, P. M.; "Serum Antibodies Reactive With <i>Saccharomyces Cerevisiae</i> in Inflammatory Bowel Disease: Is IgA Antibody a Marker for Crohn's Disease?;" <i>Int. Arch. Allergy Appl. Immunol.</i> ; 1990; 92 (1); 9-15	
		BARTLETT, J. G.; "Treatment of Antibiotic-Associated Pseudomembranous Colitis;" <i>Rev Infect Dis</i> ; 1984; 6 (Suppl 1); S235-S241	
		BASKIN, D. G.; HAHN, T. M.; and SCHWARTZ, M. W.; "Leptin Sensitive Neurons in the Hypothalamus;" <i>Horm. Metab Res.</i> ; May 1999; 31 (5); 345-350; Abstract Only	
		BELL, I. R.; BALDWIN, C. M.; and SCHWARTZ, G. E.; "Illness From Low Levels of Environmental Chemicals: Relevance to Chronic Fatigue Syndrome and Fibromyalgia;" <i>Am J Med.</i> ; September 1998; 105 (3A); 74S-82S	
		BENNETT, G.; AL-RASHED, S.; HOULT, J. R.; and BRAIN, S. D.; "Nerve Growth Factor Induced Hyperalgesia in the Rat Hind Paw Is Dependent on Circulating Neutrophils;" <i>Pain</i> ; September 1998; 77 (3); 315-322	
		BERGSTROM, J.; "Mechanisms of Uremic Suppression of Appetite;" <i>J Ren Nutr.</i> ; July 1999; 9 (3); 129-132; Abstract Only	
		BILCHIK, A. J.; HINES, O. J.; ZINNER, M. J.; ADRIAN, T. E.; BERGER, J. J.; ASHLEY, S. W.; and MCFADDEN, D. W.; "Peptide YY Augments Postprandial Small Intestinal Absorption in the Conscious Dog 1;" <i>Am. J Surg.</i> ; June 1994; 167 (6); 570-574	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/810,020
			<i>Filing Date</i>	3/26/2004
			<i>First Named Inventor</i>	Lin
			<i>Art Unit</i>	1645
			<i>Examiner Name</i>	Swartz, Rodney P.
(Use as many sheets as necessary)			<i>Attorney Docket Number</i>	04-11US
Sheet	11	of	41	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BJORNSSON, E. S. and ABRAHAMSSON, H.; "Comparison Between Physiologic and Erythromycin-Induced Interdigestive Motility;" <i>Scand. J Gastroenterol.</i> ; February 1995; 30 (2); 139-145; Abstract Only	
		BLEVINS, J. E.; STANLEY, B. G.; and REIDELBERGER, R. D.; "Brain Regions Where Cholecystokinin Suppresses Feeding in Rats;" <i>Brain Res.</i> ; March 2000; 860 (1-2); 1-10	
		BOOYSE, F. M.; OSIKOWICZ, G.; and QUARFOOT, A. J.; "Effects of Chronic Oral Consumption of Nicotine on the Rabbit Aortic Endothelium;" <i>Am J Pathol.</i> ; February 1981; 102 (2); 229-238	
		BROWN, MICHAEL S. and GOLDSTEIN, JOSEPH S.; "The Hyperlipoproteinemias and Other Disorders of Lipid Metabolism;" 1994; 13 (344); 2058-2069	
		BROWN, N. J.; READ, N. W.; RICHARDSON, A.; RUMSEY, R. D.; and BOGENTOFT, C.; "Characteristics of Lipid Substances Activating the Ileal Brake in the Rat;" <i>Gut</i> ; October 1990; 31 (10); 1126-1129	
		BROWN, N. J.; FRENCH, S. J.; RUMSEY, R. D.; and READ, N. W.; "The Effect of a 5-HT ₃ -Antagonist on the Ileal Brake Mechanism in the Rat;" <i>J Pharm. Pharmacol.</i> ; July 1991; 43 (7); 517-519; Abstract Only	
		BROWN, N. J.; RUMSEY, R. D.; BOGENTOFT, C.; and READ, N. W.; "The Effect of an Opiate Receptor Antagonist on the Ileal Brake Mechanism in the Rat;" <i>Pharmacology</i> ; October 1993; 47 (4); 230-236; Abstract Only	
		BROWN, N. J.; HORTON, A.; RUMSEY, R. D.; and READ, N. W.; "Granisetron and Ondansetron: Effects on the Ileal Brake Mechanism in the Rat;" <i>J Pharm. Pharmacol.</i> ; June 1993; 45 (6); 521-524; Abstract Only	
		BRUIN, K. F.; HOMMES, D. W.; JANSEN, J.; TYTGAT, G. N.; WOUTER TEN, CATE J.; and VAN DEVENTER, S. J.; "Modulation of Cytokine Release From Human Monocytes by Drugs Used in the Therapy of Inflammatory Bowel Diseases;" <i>Eur. J Gastroenterol. Hepatol.</i> ; August 1995; 7 (8); 791-795; Abstract Only	
		BRUNO, R. L.; CREANGE, S. J.; and FRICK, N. M.; "Parallels Between Post-Polio Fatigue and Chronic Fatigue Syndrome: a Common Pathophysiology?;" <i>Am J Med.</i> ; September 1998; 105 (3A); 66S-73S	
		BUHNER, S. and EHRLEIN, H. J.; "Characteristics of Postprandial Duodenal Motor Patterns in Dogs;" <i>Dig. Dis. Sci.</i> ; December 1989; 34 (12); 1873-1881	
		BUSHNIK, T.; BIELAJEW, C.; KONKLE, A. T.; and MERALI, Z.; "Influence of Bombesin on Threshold for Feeding and Reward in the Rat;" <i>Acta Neurobiol. Exp. (Wars.)</i> ; 1999; 59 (4); 295-302; Abstract Only	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 12 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CAMMACK, J.; READ, N. W.; CANN, P. A.; GREENWOOD, B.; and HOLGATE, A. M.; "Effect of Prolonged Exercise on the Passage of a Solid Meal Through the Stomach and Small Intestine;" <i>Gut</i> ; November 1982; 23 (11); 957-961	
		CAMOGGIO, L.; TE VELDE, A. A.; TIGGES, A. J.; DAS, P. K.; and VAN DEVENTER, S. J.; "Altered Expression of Interferon-Gamma and Interleukin-4 in Inflammatory Bowel Disease;" <i>Inflamm. Bowel Dis.</i> ; November 1998; 4 (4); 285-290; Abstract Only	
		CARLSON, G. M.; RUDDON, R. W.; HUG, C. C., JR.; and BASS, P.; "Effects of Nicotine on Gastric Antral and Duodenal Contractile Activity in the Dog;" <i>J Pharmacol. Exp. Ther.</i> ; April 1970; 172 (2); 367-376	
		CASAFONT MORENCOS, F.; DE LAS HERAS, CASTANO G.; MARTIN, RAMOS L.; LOPEZ ARIAS, M. J.; LEDESMA, F.; and PONS, ROMERO F.; "Small Bowel Bacterial Overgrowth in Patients With Alcoholic Cirrhosis;" <i>Dig. Dis. Sci.</i> ; March 1996; 41 (3); 552-556; Abstract Only	
		CASELLAS, F.; CHICHARRO, L.; and MALAGELADA, J. R.; "Potential Usefulness of Hydrogen Breath Test With D-Xylose in Clinical Management of Intestinal Malabsorption;" <i>Dig. Dis. Sci.</i> ; February 1993; 38 (2); 321-327	
		CASINI-RAGGI, V.; KAM, L.; CHONG, Y. J.; FIOCCHI, C.; PIZARRO, T. T.; and COMINELLI, F.; "Mucosal Imbalance of IL-1 and IL-1 Receptor Antagonist in Inflammatory Bowel Disease. A Novel Mechanism of Chronic Intestinal Inflammation;" <i>J Immunol.</i> ; March 1995; 154 (5); 2434-2440; Abstract Only	
		CASTEDAL, M.; BJORNSSON, E.; and ABRAHAMSSON, H.; "Postprandial Peristalsis in the Human Duodenum;" <i>Neurogastroenterol. Motil.</i> ; June 1998; 10 (3); 227-233; Abstract Only	
		CATER, R. E.; "The Clinical Importance of Hypochlorhydria (a Consequence of Chronic Helicobacter Infection): Its Possible Etiological Role in Mineral and Amino Acid Malabsorption, Depression, and Other Syndromes;" <i>Med. Hypotheses</i> ; December 1992; 39 (4); 375-383	
		CHANG, C. S.; CHEN, G. H.; KAO, C. H.; WANG, S. J.; PENG, S. N.; HUANG, C. K.; and POON, S. K.; "Increased Accuracy of the Carbon-14 D-Xylose Breath Test in Detecting Small-Intestinal Bacterial Overgrowth by Correction With the Gastric Emptying Rate;" <i>Eur. J Nucl. Med.</i> ; October 1995; 22 (10); 1118-1122; Abstract Only	
		CHANG, C. S.; CHEN, G. H.; LIEN, H. C.; and YEH, H. Z.; "Small Intestine Dysmotility and Bacterial Overgrowth in Cirrhotic Patients With Spontaneous Bacterial Peritonitis;" <i>Hepatology</i> ; November 1998; 28 (5); 1187-1190; Abstract Only	
		CHEN, J. X.; PAN, H.; ROTHMAN, T. P.; WADE, P. R.; and GERSHON, M. D.; "Guinea Pig 5-HT Transporter: Cloning, Expression, Distribution, and Function in Intestinal Sensory Reception;" <i>Am J Physiol</i> ; September 1998; 275 (3 Pt 1); G433-G448; Abstract Only	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	13	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHERBUT, C.; AUBE, A. C.; BLOTTIERE, H. M.; and GALMICHE, J. P.; "Effects of Short-Chain Fatty Acids on Gastrointestinal Motility;" <i>Scand. J Gastroenterol. Suppl</i> ; 1997; 222 58-61; Abstract Only	
		CHESTA, J.; DEFILIPPI, C.; and DEFILIPPI, C.; "Abnormalities in Proximal Small Bowel Motility in Patients With Cirrhosis;" <i>Hepatology</i> ; May 1993; 17 (5); 828-832; Abstract Only	
		CHRISTOPHE, J.; "Is There Appetite After GLP-1 and PACAP?;" <i>Ann. N. Y. Acad. Sci.</i> ; December 1998; 865 323-335; Abstract Only	
		COHN, C.; "Meal-Eating, Nibbling, and Body Metabolism;" <i>J Am Diet. Assoc.</i> ; May 1961; 38 433-436	
		COHN, C.; "FEEDING PATTERNS AND SOME ASPECTS OF CHOLESTEROL METABOLISM;" <i>Fed. Proc.</i> ; January 1964; 23 76-81	
		COLLINS, S. M.; CONOVER, K. L.; FORSYTH, P. A.; and WEINGARTEN, H. P.; "Endogenous Cholecystokinin and Intestinal Satiety;" <i>Am J Physiol</i> ; December 1985; 249 (6 Pt 2); R667-R671; Abstract Only	
		COMINELLI, F. and PIZARRO, T. T.; "Interleukin-1 and Interleukin-1 Receptor Antagonist in Inflammatory Bowel Disease;" <i>Aliment. Pharmacol. Ther.</i> ; 1996; 10 Suppl 2 49-53; Abstract Only	
		CORAZZA, G.; STROCCHI, A.; SORGE, M.; BENTAI, G.; and GASBARRINI, G.; "Prevalence and Consistency of Low Breath H ₂ Excretion Following Lactulose Ingestion. Possible Implications for the Clinical Use of the H ₂ Breath Test;" <i>Dig. Dis. Sci.</i> ; November 1993; 38 (11); 2010-2016; Abstract Only	
		CORAZZA, G. R.; MENOZZI, M. G.; STROCCHI, A.; RASCITI, L.; VAIRA, D.; LECCHINI, R.; AVANZINI, P.; CHEZZI, C.; and GASBARRINI, G.; "The Diagnosis of Small Bowel Bacterial Overgrowth. Reliability of Jejunal Culture and Inadequacy of Breath Hydrogen Testing;" <i>Gastroenterology</i> ; February 1990; 98 (2); 302-309; Abstract Only	
		COSTELLO, A. J.; "The Effect of an Elemental Diet on Stool Output in Irritable Bowel Syndrome;" <i>Proceedings of the Nutrition Society</i> ; 1994; 53 (3), 223A	
		CROSS-MELLOR, S. K.; KAVALIERS, M.; and OSSENKOPP, K. P.; "Repeated Injections of Lipopolysaccharide Attenuate the Satiety Effects of Cholecystokinin;" <i>Neuroreport</i> ; December 1999; 10 (18); 3847-3851; Abstract Only	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	14	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CULPEPPER-MORGAN, J. A.; INTURRISI, C. E.; PORTENOY, R. K.; FOLEY, K.; HOUE, R. W.; MARSH, F.; and KREEK, M. J.; "Treatment of Opioid-Induced Constipation With Oral Naloxone: a Pilot Study;" <i>Clin Pharmacol. Ther.</i> ; July 1992; 52 (1); 90-95; Abstract Only	
		CUMMINGS, J. H. and MACFARLANE, G. T.; "The Control and Consequences of Bacterial Fermentation in the Human Colon;" <i>J Appl. Bacteriol.</i> ; June 1991; 70 (6); 443-459	
		CUNNINGHAM, K. M.; DALY, J.; HOROWITZ, M.; and READ, N. W.; "Gastrointestinal Adaptation to Diets of Differing Fat Composition in Human Volunteers;" <i>Gut</i> ; May 1991; 32 (5); 483-486	
		CUOCO, L.; CAMMAROTA, G.; JORIZZO, R.; and GASBARRINI, G.; "Small Intestinal Bacterial Overgrowth and Symptoms of Irritable Bowel Syndrome;" <i>Am J Gastroenterol.</i> ; July 2001; 96 (7); 2281-2282	
		DAIG, R.; ANDUS, T.; ASCHENBRENNER, E.; FALK, W.; SCHOLMERICH, J.; and GROSS, V.; "Increased Interleukin 8 Expression in the Colon Mucosa of Patients With Inflammatory Bowel Disease;" <i>Gut</i> ; February 1996; 38 (2); 216-222; Abstract Only	
		DANTZER, R.; BLUTHE, R. M.; LAYE, S.; BRET-DIBAT, J. L.; PARNET, P.; and KELLEY, K. W.; "Cytokines and Sickness Behavior;" <i>Ann. N. Y. Acad. Sci.</i> ; May 1998; 840 586-590	
		DARROCH, C. J.; BARNES, R. M.; and DAWSON, J.; "Circulating Antibodies to <i>Saccharomyces Cerevisiae</i> (Bakers/Brewers' Yeast) in Gastrointestinal Disease;" <i>J Clin Pathol.</i> ; January 1999; 52 (1); 47-53	
		DAVIS, STANLEY S.; STOCKWELL, ANITA F.; MARGARET J. TAYLOR; JOHN G. HARDY; DAVID R. WHALLEY; C.G. WILSON; HELLE BECHGAARD; and FINN N. CHRISTENSEN; "The Effect of Density on the Gastric Emptying of Single- and Multiple-Unit Dosage Forms;" <i>Pharmaceutical Research</i> ; 1986; 3 (4); 208-213	
		DE CAMPOS, R. O.; HENRIQUES, M. G.; and CALIXTO, J. B.; "Systemic Treatment With <i>Mycobacterium Bovis Bacillus Calmette-Guerin</i> (BCG) Potentiates Kinin B1 Receptor Agonist-Induced Nociception and Oedema Formation in the Formalin Test in Mice;" <i>Neuropeptides</i> ; October 1998; 32 (5); 393-403	
		DE BECKER, P.; DENDALE, P.; DE, MEIRLEIR K.; CAMPINE, I.; VANDENBORNE, K.; and HAGERS, Y.; "Autonomic Testing in Patients With Chronic Fatigue Syndrome;" <i>Am J Med.</i> ; September 1998; 105 (3A); 22S-26S	
		DE BOISSIEU, D.; CHAUSSAIN, M.; BADOUAL, J.; RAYMOND, J.; and DUPONT, C.; "Small-Bowel Bacterial Overgrowth in Children With Chronic Diarrhea, Abdominal Pain, or Both;" <i>J Pediatr.</i> ; February 1996; 128 (2); 203-207	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	15	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DELIN, N. A.; AXELSSON, B.; JOHANSSON, C.; and POPPEN, B.; "Comparison of Gamma Camera and Withdrawal Methods for the Measurement of Gastric Emptying;" <i>Scand. J Gastroenterol.</i> ; 1978; 13 (7); 867-872	
		DELLERT, S. F.; NOWICKI, M. J.; FARRELL, M. K.; DELENTE, J.; and HEUBI, J. E.; "The 13C-Xylose Breath Test for the Diagnosis of Small Bowel Bacterial Overgrowth in Children;" <i>J Pediatr. Gastroenterol. Nutr.</i> ; August 1997; 25 (2); 153-158	
		DEMITRACK, M. A.; "Neuroendocrine Aspects of Chronic Fatigue Syndrome: a Commentary;" <i>Am J Med.</i> ; September 1998; 105 (3A); 11S-14S	
		DINARELLO, C. A.; "Role of Pro- and Anti-Inflammatory Cytokines During Inflammation: Experimental and Clinical Findings;" <i>J Biol. Regul. Homeost. Agents</i> ; July 1997; 11 (3); 91-103; Abstract Only	
		DOBSON, C. L.; DAVIS, S. S.; CHAUHAN, S.; SPARROW, R. A.; and WILDING, I. R.; "The Effect of Oleic Acid on the Human Ileal Brake and Its Implications for Small Intestinal Transit of Tablet Formulations;" <i>Pharm. Res.</i> ; January 1999; 16 (1); 92-96	
		DREZNIK, Z.; MEININGER, T. A.; BARTEAU, J. A.; BROCKSMITH, D.; and SOPER, N. J.; "Effect of Ileal Oleate on Interdigestive Intestinal Motility of the Dog;" <i>Dig. Dis. Sci.</i> ; July 1994; 39 (7); 1511-1518	
		DROSSMAN, D. A.; PATRICK, D. L.; WHITEHEAD, W. E.; TONER, B. B.; DIAMANT, N. E.; HU, Y.; JIA, H.; and BANGDIWALA, S. I.; "Further Validation of the IBS-QOL: a Disease-Specific Quality-of-Life Questionnaire;" <i>Am J Gastroenterol.</i> ; April 2000; 95 (4); 999-1007	
		EBERLE-WANG, K. and SIMANSKY, K. J.; "The CCK-A Receptor Antagonist, Devazepide, Blocks the Anorectic Action of CCK but Not Peripheral Serotonin in Rats;" <i>Pharmacol. Biochem. Behav.</i> ; November 1992; 43 (3); 943-947; Abstract Only	
		EDES, T. E.; WALK, B. E.; and AUSTIN, J. L.; "Diarrhea in Tube-Fed Patients: Feeding Formula Not Necessarily the Cause;" <i>Am J Med.</i> ; February 1990; 88 (2); 91-93	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	16	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EDWARDS, S. and STEVENS, R.; "Peripherally Administered 5-Hydroxytryptamine Elicits the Full Behavioural Sequence of Satiety;" <i>Physiol Behav.</i> ; November 1991; 50 (5); 1075-1077	
		EL-SALHY, M. and NORRGARD, O.; "Colonic Neuroendocrine Peptide Levels in Patients With Chronic Idiopathic Slow Transit Constipation;" <i>Ups. J Med. Sci.</i> ; 1998; 103 (3); 223-230; Abstract Only	
		ERICKSON, J. C.; HOLLOPETER, G.; and PALMITER, R. D.; "Attenuation of the Obesity Syndrome of Ob/Ob Mice by the Loss of Neuropeptide Y;" <i>Science</i> ; December 1996; 274 (5293); 1704-1707	
		EVANS, P. R.; BAK, Y. T.; SHUTER, B.; HOSCHL, R.; and KELLOW, J. E.; "Gastroparesis and Small Bowel Dysmotility in Irritable Bowel Syndrome;" <i>Dig. Dis. Sci.</i> ; October 1997; 42 (10); 2087-2093; Abstract Only	
		FARAONE, S. V.; BIEDERMAN, J.; WEBER, W.; and RUSSELL, R. L.; "Psychiatric, Neuropsychological, and Psychosocial Features of DSM-IV Subtypes of Attention-Deficit/Hyperactivity Disorder: Results From a Clinically Referred Sample;" <i>J Am Acad. Child Adolesc. Psychiatry</i> ; February 1998; 37 (2); 185-193; Abstract Only	
		FARIS, P. L.; KIM, S. W.; MELLER, W. H.; GOODALE, R. L.; OAKMAN, S. A.; HOFBAUER, R. D.; MARSHALL, A. M.; DAUGHTERS, R. S.; BANERJEE-STEVENS, D.; ECKERT, E. D.; and HARTMAN, B. K.; "Effect of Decreasing Afferent Vagal Activity With Ondansetron on Symptoms of Bulimia Nervosa: a Randomised, Double-Blind Trial;" <i>Lancet</i> ; March 2000; 355 (9206); 792-797; Abstract Only	
		FARTHING, M. J.; "5-Hydroxytryptamine and 5-Hydroxytryptamine-3 Receptor Antagonists;" <i>Scand. J Gastroenterol. Suppl</i> ; 1991; 188 92-100; Abstract Only	
		FARUP, P. G.; HOVDENAK, N.; WETTERHUS, S.; LANGE, O. J.; HOVDE, O.; and TRONDSTAD, R.; "The Symptomatic Effect of Cisapride in Patients With Irritable Bowel Syndrome and Constipation;" <i>Scand. J Gastroenterol.</i> ; February 1998; 33 (2); 128-131	
		FAUSA, L.E. et al; "Crohn's Disease. Clinical Manifestations." <i>Scand J Gastroenterol</i> ; August 1985; 20 (6); 665-670	
		FEGHALI, C. A. and WRIGHT, T. M.; "Cytokines in Acute and Chronic Inflammation;" <i>Front Biosci.</i> ; January 1997; 2 d12-d26; Abstract Only	
		FEHER, E.; KOVACS, A.; GALLATZ, K.; and FEHER, J.; "Direct Morphological Evidence of Neuroimmunomodulation in Colonic Mucosa of Patients With Crohn's Disease;" <i>Neuroimmunomodulation.</i> ; September 1997; 4 (5-6); 250-257; Abstract Only	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 17 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FELLERMANN, K.; LUDWIG, D.; STAHL, M.; VID-WALEK, T.; and STANGE, E. F.; "Steroid-Unresponsive Acute Attacks of Inflammatory Bowel Disease: Immunomodulation by Tacrolimus (FK506);" <i>Am J Gastroenterol.</i> ; October 1998; 93 (10); 1860-1866; Abstract Only	
		FENNER, H.; "[Immunopharmacologic Profile and Therapeutic Prospects of Anti-TNF-Alpha Therapy];" <i>Z. Rheumatol.</i> ; October 1998; 57 (5); 294-297; Abstract Only	
		FERRARA, A.; ZINNER, M. J.; HINSDALE, J. G.; and JAFFE, B. M.; "Intraluminal Release of Serotonin During the Interdigestive Migrating Complex in the Canine Small Intestine;" <i>J Surg. Res.</i> ; September 1986; 41 (3); 308-311; Abstract Only	
		FERRARA, A.; ZINNER, M. J.; and JAFFE, B. M.; "Intraluminal Release of Serotonin, Substance P, and Gastrin in the Canine Small Intestine;" <i>Dig. Dis. Sci.</i> ; March 1987; 32 (3); 289-294; Abstract Only	
		FOX-THRELKELD, J. A.; DANIEL, E. E.; CHRISTINCK, F.; WOSKOWSKA, Z.; CIPRIS, S.; and MCDONALD, T. J.; "Peptide YY Stimulates Circular Muscle Contractions of the Isolated Perfused Canine Ileum by Inhibiting Nitric Oxide Release and Enhancing Acetylcholine Release;" <i>Peptides</i> ; November 1993; 14 (6); 1171-1178; Abstract Only	
		FOXX-ORENSTEIN, A. E.; JIN, J. G.; and GRIDER, J. R.; "5-HT ₄ Receptor Agonists and Delta-Opioid Receptor Antagonists Act Synergistically to Stimulate Colonic Propulsion;" <i>Am J Physiol</i> ; November 1998; 275 (5 Pt 1); G979-G983; Abstract Only	
		FRANCIS, C. Y.; MORRIS, J.; and WHORWELL, P. J.; "The Irritable Bowel Severity Scoring System: a Simple Method of Monitoring Irritable Bowel Syndrome and Its Progress;" <i>Aliment. Pharmacol. Ther.</i> ; April 1997; 11 (2); 395-402; Abstract Only	
		FRANKENFIELD, D. C. and BEYER, P. L.; "Soy-Polysaccharide Fiber: Effect on Diarrhea in Tube-Fed, Head-Injured Patients;" <i>Am J Clin Nutr.</i> ; September 1989; 50 (3); 533-538; Abstract Only	
		FRASER, R.; CLIFF, W. J.; and COURTICE, F. C.; "The Effect of Dietary Fat Load on the Size and Composition of Chylomicrons in Thoracic Duct Lymph;" <i>Q. J. Exp. Physiol Cogn Med. Sci.</i> ; October 1968; 53 (4); 390-398	
		FRIEDMAN, G.; "Diet and the Irritable Bowel Syndrome;" <i>Gastroenterol. Clin North Am</i> ; June 1991; 20 (2); 313-324;	
		FU, L. W. and LONGHURST, J. C.; "Role of 5-HT ₃ Receptors in Activation of Abdominal Sympathetic C Fibre Afferents During Ischaemia in Cats;" <i>J Physiol</i> ; June 1998; 509 (Pt 3) 729-740; Abstract Only	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	18	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FUJIMIYA, M.; MIYAZAKI, M.; FUJIMURA, M.; and KIMURA, H.; "Effect of Carbachol on the Release of Peptide YY From Isolated Vascularly and Luminally Perfused Rat Ileum;" <i>Peptides</i> ; 1995; 16 (5); 939-944; Abstract Only	
		FUNAKOSHI, K.; SUGIMURA, K.; ANEZAKI, K.; BANNAI, H.; ISHIZUKA, K.; and ASAKURA, H.; "Spectrum of Cytokine Gene Expression in Intestinal Mucosal Lesions of Crohn's Disease and Ulcerative Colitis;" <i>Digestion</i> ; 1998; 59 (1); 73-78; Abstract Only	
		YUJI FUNAYAMA; IWAO SASAKI; HIROO NAITO; KOHEI FUKUSHIMA; TSUYOSHI MASUKO; KEN-ICHI TAKAHASHI; HITOSHI OGAWA; SHUN SATO; TATSUYA UENO; MITSUNORI NAGUCHI; NOBUO HIWATASHI; and SEIKI MATSUNO; "Anti-Bacterial Treatment for Postoperative Bacterial Overgrowth in Crohn's Disease;" <i>Minerva Gastroenterol. Dietol.</i> ; May 1997; 112 (4 Suppl.); A1444; Abstract Only	
		GALATOLA, G.; GROSSO, M.; BARLOTTA, A.; FERRARIS, R.; ROVERA, L.; ARIANO, M.; COTTINO, F.; and DE LA, PIERRE M.; "[Diagnosis of Bacterial Contamination of the Small Intestine Using the 1 g [14C] Xylose Breath Test in Various Gastrointestinal Diseases];" <i>Minerva Gastroenterol. Dietol.</i> ; July 1991; 37 (3); 169-175; Abstract Only	
		GALLIGAN, J. J.; "Electrophysiological Studies of 5-Hydroxytryptamine Receptors on Enteric Neurons;" <i>Behav. Brain Res.</i> ; 1996; 73 (1-2); 199-201; Abstract Only	
		GARDINER, G.; ROSS, R. P.; COLLINS, J. K.; FITZGERALD, G.; and STANTON, C.; "Development of a Probiotic Cheddar Cheese Containing Human-Derived Lactobacillus Paracasei Strains;" <i>Appl. Environ. Microbiol.</i> ; June 1998; 64 (6); 2192-2199	
		GERSHON, M. D.; WADE, P. R.; KIRCHGESSNER, A. L.; and TAMIR, H.; "5-HT Receptor Subtypes Outside the Central Nervous System. Roles in the Physiology of the Gut;" <i>Neuropsychopharmacology</i> ; October 1990; 3 (5-6); 385-395; Abstract Only	
		GERSHON, M. D.; "Serotonin: Its Role and Receptors in Enteric Neurotransmission;" <i>Adv. Exp. Med. Biol.</i> ; 1991; 294 221-230; Abstract Only	
		GERSHON, M. D.; "Review Article: Roles Played by 5-Hydroxytryptamine in the Physiology of the Bowel;" <i>Aliment. Pharmacol. Ther.</i> ; May 1999; 13 Suppl 2 15-30; Abstract Only	
		GIELKENS, H. A.; NIEUWENHUIZEN, A.; BIEMOND, I.; LAMERS, C. B.; and MASCLEE, A. A.; "Interdigestive Antroduodenal Motility and Gastric Acid Secretion;" <i>Aliment. Pharmacol. Ther.</i> ; January 1998; 12 (1); 27-33; Abstract Only	
		GIRALT, M. and VERGARA, P.; "Both Afferent and Efferent Nerves Are Implicated in Cholecystokinin Motor Actions in the Small Intestine of the Rat;" <i>Regul. Pept.</i> ; May 1999; 81 (1-3); 73-80; Abstract Only	
		GIRARDET, R. E. and BENNINGHOFF, D. L.; "Surgical Techniques for Long-Term Study of Thoracic Duct Lymph Circulation in Dogs;" <i>J Surg. Res.</i> ; September 1973; 15 (3); 168-175	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 19 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GLASER, R. and KIECOLT-GLASER, J. K.; "Stress-Associated Immune Modulation: Relevance to Viral Infections and Chronic Fatigue Syndrome;" <i>Am J Med.</i> ; September 1998; 105 (3A); 35S-42S	
		GORARD, D. A. and FARTHING, M. J.; "Intestinal Motor Function in Irritable Bowel Syndrome;" <i>Dig. Dis.</i> ; March 1994; 12 (2); 72-84; Abstract Only	
		GORARD, D. A.; LIBBY, G. W.; and FARTHING, M. J.; "Ambulatory Small Intestinal Motility in 'Diarrhea' Predominant Irritable Bowel Syndrome;" <i>Gut</i> ; February 1994; 35 (2); 203-210	
		GOTZ, V. P. and RAND, K. H.; "Medical Management of Antimicrobial-Associated Diarrhea and Colitis;" <i>Pharmacotherapy</i> ; March 1982; 2 (2); 100-109	
		GRIDER, J. R.; FOXX-ORENSTEIN, A. E.; and JIN, J. G.; "5-Hydroxytryptamine ₄ Receptor Agonists Initiate the Peristaltic Reflex in Human, Rat, and Guinea Pig Intestine;" <i>Gastroenterology</i> ; August 1998; 115 (2); 370-380; Abstract Only	
		GROLL, D.; VANNER, S. J.; DEPEW, W. T.; DACOSTA, L. R.; SIMON, J. B.; GROLL, A.; ROBLIN, N.; and PATERSON, W. G.; "The IBS-36: a New Quality of Life Measure for Irritable Bowel Syndrome;" <i>Am J Gastroenterol.</i> ; April 2002; 97 (4); 962-971	
		GRUY-KAPRAL, C.; LITTLE, K. H.; FORDTRAN, J. S.; MEZIERE, T. L.; HAGEY, L. R.; and HOFMANN, A. F.; "Conjugated Bile Acid Replacement Therapy for Short-Bowel Syndrome;" <i>Gastroenterology</i> ; January 1999; 116 (1); 15-21	
		GUE, M.; JUNIEN, J. L.; REEVE, J. R., JR.; RIVIER, J.; GRANDT, D.; and TACHE, Y.; "Reversal by NPY, PYY and 3-36 Molecular Forms of NPY and PYY of Intracisternal CRF-Induced Inhibition of Gastric Acid Secretion in Rats 1;" <i>Br. J. Pharmacol.</i> ; May 1996; 118 (2); 237-242	
		GUIMBAUD, R.; BERTRAND, V.; CHAUVELOT-MOACHON, L.; QUARTIER, G.; VIDON, N.; GIROUD, J. P.; COUTURIER, D.; and CHAUSSADE, S.; "Network of Inflammatory Cytokines and Correlation With Disease Activity in Ulcerative Colitis;" <i>Am J Gastroenterol.</i> ; December 1998; 93 (12); 2397-2404; Abstract Only	
		GUNN, M. C.; CAVIN, A. A.; and MANSFIELD, J. C.; "Management of Irritable Bowel Syndrome;" <i>Postgrad. Med. J.</i> ; March 2003; 79 (929); 154-158	
		GWINUP, G.; BYRON, R. C.; ROUSH, W. H.; KRUGER, F. A.; and HAMWI, G. J.; "EFFECT OF NIBBLING VERSUS GORGING ON SERUM LIPIDS IN MAN;" <i>Am J Clin Nutr.</i> ; October 1963; 13 209-213	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known Application Number 10/810,020 Filing Date 3/26/2004 First Named Inventor Lin Art Unit 1645 Examiner Name Swartz, Rodney P. Attorney Docket Number 04-11US			Sheet	20	of	41

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HANG, L.; WULLT, B.; SHEN, Z.; KARPMAN, D.; and SVANBORG, C.; "Cytokine Repertoire of Epithelial Cells Lining the Human Urinary Tract;" <i>J Urol.</i> ; June 1998; 159 (6); 2185-2192; Abstract Only	
		HARLOW, B. L.; SIGNORELLO, L. B.; HALL, J. E.; DAILEY, C.; and KOMAROFF, A. L.; "Reproductive Correlates of Chronic Fatigue Syndrome;" <i>Am J Med.</i> ; September 1998; 105 (3A); 94S-99S	
		HAYASHI, HIROSHI et al; "Fat Feeding Increases Size, but Not Number, of Chylomicrons produced by small intestine;" <i>The American Physiological Society</i> ; Chapter 22, G709-G719; 1990	
		HELLSTROM, P. M.; NILSSON, I.; and SVENBERG, T.; "Role of Bile in Regulation of Gut Motility;" <i>J Intern. Med.</i> ; April 1995; 237 (4); 395-402; Abstract Only	
		HOLLOPETER, G.; ERICKSON, J. C.; SEELEY, R. J.; MARSH, D. J.; and PALMITER, R. D.; "Response of Neuropeptide Y-Deficient Mice to Feeding Effectors;" <i>Regul. Pept.</i> ; September 1998; 75-76 383-389; Abstract Only	
		HORI, T.; OKA, T.; HOSOI, M.; and AOU, S.; "Pain Modulatory Actions of Cytokines and Prostaglandin E2 in the Brain;" <i>Ann. N. Y. Acad. Sci.</i> ; May 1998; 840 269-281; Abstract Only	
		HUDZIAK, J. J.; HEATH, A. C.; MADDEN, P. F.; REICH, W.; BUCHOLZ, K. K.; SLUTSKE, W.; BIERUT, L. J.; NEUMAN, R. J.; and TODD, R. D.; "Latent Class and Factor Analysis of DSM-IV ADHD: a Twin Study of Female Adolescents;" <i>J Am Acad. Child Adolesc. Psychiatry</i> ; August 1998; 37 (8); 848-857; Abstract Only	
		HUGE, A.; WEBER, E.; and EHRLEIN, H. J.; "Effects of Enteral Feedback Inhibition on Motility, Luminal Flow, and Absorption of Nutrients in Proximal Gut of Minipigs;" <i>Dig. Dis. Sci.</i> ; May 1995; 40 (5); 1024-1034	
		HUGHES, J. J.; LEVINE, A. S.; MORLEY, J. E.; GOSNELL, B. A.; and SILVIS, S. E.; "Intraventricular Calcitonin Gene-Related Peptide Inhibits Gastric Acid Secretion;" <i>Peptides</i> ; July 1984; 5 (4); 665-667	
		HYAMS, J. S.; FITZGERALD, J. E.; WYZGA, N.; MULLER, R.; TREEM, W. R.; JUSTINICH, C. J.; and KREUTZER, D. L.; "Relationship of Interleukin-1 Receptor Antagonist to Mucosal Inflammation in Inflammatory Bowel Disease;" <i>J Pediatr. Gastroenterol. Nutr.</i> ; November 1995; 21 (4); 419-425; Abstract Only	
		INUI, A.; "Feeding and Body-Weight Regulation by Hypothalamic Neuropeptides—Mediation of the Actions of Leptin;" <i>Trends Neurosci.</i> ; February 1999; 22 (2); 62-67; Abstract Only	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/810,020
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
(Use as many sheets as necessary)				Attorney Docket Number	04-11US
Sheet	21	of	41		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		IRWIN, M. I. and FEELEY, R. M.; "Frequency and Size of Meals and Serum Lipids, Nitrogen and Mineral Retention, Fat Digestibility, and Urinary Thiamine and Riboflavin in Young Women;" <i>Am J Clin Nutr.</i> ; August 1967; 20 (8); 816-824	
		JACKEROTT, M. and LARSSON, L. I.; "Immunocytochemical Localization of the NPY/PYY Y1 Receptor in Enteric Neurons, Endothelial Cells, and Endocrine-Like Cells of the Rat Intestinal Tract;" <i>J Histochem. Cytochem.</i> ; December 1997; 45 (12); 1643-1650; Abstract Only	
		JAGANNATHAN, S. N.; CONNELL, W. F.; and BEVERIDGE, J. M.; "EFFECTS OF GORMANDIZING AND SEMICONTINUOUS EATING OF EQUICALORIC AMOUNTS OF FORMULA-TYPE HIGH FAT DIETS ON PLASMA CHOLESTEROL AND TRIGLYCERIDE LEVELS IN HUMAN VOLUNTEER SUBJECTS;" <i>Am J Clin Nutr.</i> ; August 1964; 15 90-93	
		JASON, L. A.; WAGNER, L.; ROSENTHAL, S.; GOODLATTE, J.; LIPKIN, D.; PAPERNIK, M.; PLIOPLYS, S.; and PLIOPLYS, A. V.; "Estimating the Prevalence of Chronic Fatigue Syndrome Among Nurses;" <i>Am J Med.</i> ; September 1998; 105 (3A); 91S-93S	
		JENKINS, D. J.; WOLEVER, T. M.; VUKSAN, V.; BRIGHENTI, F.; CUNNANE, S. C.; RAO, A. V.; JENKINS, A. L.; BUCKLEY, G.; PATTEN, R.; SINGER, W.; and .; "Nibbling Versus Gorging: Metabolic Advantages of Increased Meal Frequency;" <i>N. Engl. J Med.</i> ; October 1989; 321 (14); 929-934	
		JENKINS, P. J.; HARPER, R. W.; and NESTEL, P. J.; "Severity of Coronary Atherosclerosis Related to Lipoprotein Concentration;" <i>Br. Med. J.</i> ; August 1978; 2 (6134); 388-391	
		JIN, J. G.; FOXX-ORENSTEIN, A. E.; and GRIDER, J. R.; "Propulsion in Guinea Pig Colon Induced by 5-Hydroxytryptamine (HT) Via 5-HT4 and 5-HT3 Receptors;" <i>J Pharmacol. Exp. Ther.</i> ; January 1999; 288 (1); 93-97; Abstract Only	
		KANIK, K. S.; HAGIWARA, E.; YARBORO, C. H.; SCHUMACHER, H. R.; WILDER, R. L.; and KLINMAN, D. M.; "Distinct Patterns of Cytokine Secretion Characterize New Onset Synovitis Versus Chronic Rheumatoid Arthritis;" <i>J Rheumatol.</i> ; January 1998; 25 (1); 16-22; Abstract Only	
		KARCHER, R. E.; TRUDING, R. M.; and STAWICK, L. E.; "Using a Cutoff of <10 Ppm for Breath Hydrogen Testing: a Review of Five Years' Experience;" <i>Ann. Clin Lab Sci.</i> ; January 1999; 29 (1); 1-8	
		KEINKE, O. and EHRLEIN, H. J.; "Effect of Oleic Acid on Canine Gastroduodenal Motility, Pyloric Diameter and Gastric Emptying;" <i>Q. J Exp. Physiol.</i> ; October 1983; 68 (4); 675-686	
		KEINKE, O.; SCHEMANN, M.; and EHRLEIN, H. J.; "Mechanical Factors Regulating Gastric Emptying of Viscous Nutrient Meals in Dogs;" <i>Q. J Exp. Physiol.</i> ; October 1984; 69 (4); 781-795	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	22	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KELLOW, J. E.; ECKERSLEY, C. M.; and JONES, M. P.; "Enhanced Perception of Physiological Intestinal Motility in the Irritable Bowel Syndrome;" <i>Gastroenterology</i> ; December 1991; 101 (6); 1621-1627; Abstract Only	
		KELLUM, J. M.; ALBUQUERQUE, F. C.; STONER, M. C.; and HARRIS, R. P.; "Stroking Human Jejunal Mucosa Induces 5-HT Release and Cl- Secretion Via Afferent Neurons and 5-HT4 Receptors;" <i>Am J Physiol</i> ; September 1999; 277 (3 Pt 1); G515-G520; Abstract Only	
		KERLIN, P. and WONG, L.; "Breath Hydrogen Testing in Bacterial Overgrowth of the Small Intestine;" <i>Gastroenterology</i> ; October 1988; 95 (4); 982-988; Abstract Only	
		KHOSLA, R. and DAVIS, S. S.; "The Effect of Polycarophil on the Gastric Emptying of Pellets;" <i>J Pharm. Pharmacol.</i> ; January 1987; 39 (1); 47-49	
		KING, C. E. and TOSKES, P. P.; "Breath Tests in the Diagnosis of Small Intestine Bacterial Overgrowth;" <i>Crit Rev. Clin Lab Sci.</i> ; 1984; 21 (3); 269-281	
		KING, C. E. and TOSKES, P. P.; "Comparison of the 1-Gram [14C]Xylose, 10-Gram Lactulose-H2, and 80-Gram Glucose-H2 Breath Tests in Patients With Small Intestine Bacterial Overgrowth;" <i>Gastroenterology</i> ; December 1986; 91 (6); 1447-1451; Abstract Only	
		KING, P. J.; WIDDOWSON, P. S.; DOODS, H. N.; and WILLIAMS, G.; "Regulation of Neuropeptide Y Release by Neuropeptide Y Receptor Ligands and Calcium Channel Antagonists in Hypothalamic Slices;" <i>J Neurochem.</i> ; August 1999; 73 (2); 641-646; Abstract Only	
		KING, P. J.; WIDDOWSON, P. S.; DOODS, H.; and WILLIAMS, G.; "Effect of Cytokines on Hypothalamic Neuropeptide Y Release in Vitro;" <i>Peptides</i> ; January 2000; 21 (1); 143-146; Abstract Only	
		KING, P. J.; WIDDOWSON, P. S.; DOODS, H.; and WILLIAMS, G.; "Regulation of Neuropeptide Y Release From Hypothalamic Slices by Melanocortin-4 Agonists and Leptin;" <i>Peptides</i> ; January 2000; 21 (1); 45-48; Abstract Only	
		KING, T. S.; ELIA, M.; and HUNTER, J. O.; "Abnormal Colonic Fermentation in Irritable Bowel Syndrome;" <i>Lancet</i> ; October 1998; 352 (9135); 1187-1189	
		KIRCHGESSNER, A. L.; LIU, M. T.; RAYMOND, J. R.; and GERSHON, M. D.; "Identification of Cells That Express 5-Hydroxytryptamine1A Receptors in the Nervous Systems of the Bowel and Pancreas;" <i>J Comp Neurol.</i> ; January 1996; 364 (3); 439-455; Abstract Only	
		KITCHENER, S. J. and DOURISH, C. T.; "An Examination of the Behavioural Specificity of Hypophagia Induced by 5-HT1B, 5-HT1C and 5-HT2 Receptor Agonists Using the Post-Prandial Satiety Sequence in Rats;" <i>Psychopharmacology (Berl)</i> ; January 1994; 113 (3-4); 369-377; Abstract Only	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 23 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KNUTSON, D.; GREENBERG, G.; and CRONAU, H.; "Management of Crohn's Disease—a Practical Approach;" <i>Am Fam. Physician</i> ; August 2003; 68 (4); 707-714	
		KOKOT, F. and FICEK, R.; "Effects of Neuropeptide Y on Appetite;" <i>Miner. Electrolyte Metab</i> ; July 1999; 25 (4-6); 303-305; Abstract Only	
		KONTULA, P.; SUIHKO, M. L.; VON, WRIGHT A.; and MATTILA-SANDHOLM, T.; "The Effect of Lactose Derivatives on Intestinal Lactic Acid Bacteria;" <i>J Dairy Sci</i> ; February 1999; 82 (2); 249-256; Abstract Only	
		KUBOYAMA, S.; "Increased Circulating Levels of Interleukin-1 Receptor Antagonist in Patients With Inflammatory Bowel Disease;" <i>Kurume Med. J</i> ; 1998; 45 (1); 33-37; Abstract Only	
		KUCHARZIK, T.; STOLL, R.; LUGERING, N.; and DOMSCHKE, W.; "Circulating Antiinflammatory Cytokine IL-10 in Patients With Inflammatory Bowel Disease (IBD);" <i>Clin Exp. Immunol</i> ; June 1995; 100 (3); 452-456; Abstract Only	
		KUCHARZIK, T.; LUGERING, N.; WEIGELT, H.; ADOLF, M.; DOMSCHKE, W.; and STOLL, R.; "Immunoregulatory Properties of IL-13 in Patients With Inflammatory Bowel Disease; Comparison With IL-4 and IL-10;" <i>Clin Exp. Immunol</i> ; June 1996; 104 (3); 483-490; Abstract Only	
		KUCHARZIK, T.; LUGERING, N.; ADOLF, M.; DOMSCHKE, W.; and STOLL, R.; "Synergistic Effect of Immunoregulatory Cytokines on Peripheral Blood Monocytes From Patients With Inflammatory Bowel Disease;" <i>Dig. Dis. Sci</i> ; April 1997; 42 (4); 805-812; Abstract Only	
		KUEMMERLE, J. F. and KELLUM, J. M.; "Serotonin Neural Receptors Mediate Motilin-Induced Motility in Isolated, Vascularly Perfused Canine Jejunum;" <i>J Surg. Res</i> ; October 1988; 45 (4); 357-362; Abstract Only	
		LAI, K. K.; MELVIN, Z. S.; MENARD, M. J.; KOTILAINEN, H. R.; and BAKER, S.; "Clostridium Difficile-Associated Diarrhea: Epidemiology, Risk Factors, and Infection Control;" <i>Infect. Control Hosp. Epidemiol</i> ; September 1997; 18 (9); 628-632	
		LAMANCA, J. J.; SISTO, S. A.; DELUCA, J.; JOHNSON, S. K.; LANGE, G.; PAREJA, J.; COOK, S.; and NATELSON, B. H.; "Influence of Exhaustive Treadmill Exercise on Cognitive Functioning in Chronic Fatigue Syndrome;" <i>Am J Med</i> ; September 1998; 105 (3A); 59S-65S	
		LANGE, G.; WANG, S.; DELUCA, J.; and NATELSON, B. H.; "Neuroimaging in Chronic Fatigue Syndrome;" <i>Am J Med</i> ; September 1998; 105 (3A); 50S-53S	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	24	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LAVIANO, A.; CANGIANO, C.; FAVA, A.; MUSCARITOLI, M.; MULIERI, G.; and ROSSI, FANELLI F.; "Peripherally Injected IL-1 Induces Anorexia and Increases Brain Tryptophan Concentrations;" <i>Adv. Exp. Med. Biol.</i> ; 1999; 467 105-108; Abstract Only	
		LEDERMAN, E.; NEUT, C.; DESREUMAUX, P.; KLEIN, O.; GAMBIEZ, L.; CORTOT, A.; and QUANDALLE, P.; "Bacterial Overgrowth in the Neoterminal Ileum After Ileocolonic Resection for Crohn's Disease;" <i>Gastroenterology</i> ; 1997; 112 (4 Suppl.); A1023-	
		LEIPER, K.; LONDON, I.; and RHODES, J. M.; "Adjuvant Post-Operative Therapy;" <i>Baillieres Clin Gastroenterol.</i> ; March 1998; 12 (1); 179-199; Abstract Only	
		LEMBCKE, B.; "[Breath Tests in Intestinal Diseases and Functional Gastrointestinal Diagnosis];" <i>Schweiz. Rundsch. Med. Prax.</i> ; June 1997; 86 (25-26); 1060-1067; Abstract Only	
		LEPIONKA, L.; MALBERT, C. H.; and LAPLACE, J. P.; "Proximal Gastric Distension Modifies Ingestion Rate in Pigs;" <i>Reprod. Nutr. Dev.</i> ; July 1997; 37 (4); 449-457; Abstract Only	
		LEVINE, P. H.; "What We Know About Chronic Fatigue Syndrome and Its Relevance to the Practicing Physician;" <i>Am J Med.</i> ; September 1998; 105 (3A); 100S-103S	
		LEWINDON, P. J.; ROBB, T. A.; MOORE, D. J.; DAVIDSON, G. P.; and MARTIN, A. J.; "Bowel Dysfunction in Cystic Fibrosis: Importance of Breath Testing;" <i>J Paediatr. Child Health</i> ; February 1998; 34 (1); 79-82; Abstract Only	
		LIN, H. C.; DOTY, J. E.; REEDY, T. J.; and MEYER, J. H.; "Inhibition of Gastric Emptying by Glucose Depends on Length of Intestine Exposed to Nutrient;" <i>Am J Physiol</i> ; February 1989; 256 (2 Pt 1); G404-G411	
		LIN, H. C.; DOTY, J. E.; REEDY, T. J.; and MEYER, J. H.; "Inhibition of Gastric Emptying by Sodium Oleate Depends on Length of Intestine Exposed to Nutrient;" <i>Am J Physiol</i> ; December 1990; 259 (6 Pt 1); G1031-G1036; Abstract Only	
		LIN, H. C.; ZHAO, X. T.; REDDY, S. N.; WANG, L. J.; and Y.-G.GU; "Inhibition of Intestinal Transit by Fat Depends on Length of Exposure to Nutrient;" <i>Gastroenterology</i> ; 1994; 106 A531; Abstract Only	
		LIN, H. C.; Y.-G.GU; and J.H.MEYER; "Acute Desensitization of Intestinal Motility Response;" <i>Gastroenterology</i> ; 1995; 103 1392-; Abstract Only	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	25	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIN, H. C.; G.BONORRIS; and J.W.MARKS; "Oleate Slows Upper Gut Transit and Reduces Diarrhea in Patients With Rapid Upper Gut Transit and Diarrhea;" <i>Gastroenterology</i> ; 1995; 108 (4); A638-	
		LIN, H. C.; ZHAO, X. T.; WANG, L.; and WONG, H.; "Fat-Induced Ileal Brake in the Dog Depends on Peptide YY;" <i>Gastroenterology</i> ; May 1996; 110 (5); 1491-1495; Abstract Only	
		LIN, H. C.; ZHAO, X. T.; CHUNG, B.; GU, Y. G.; and ELASHOFF, J. D.; "Frequency of Gastric Pacesetter Potential Depends on Volume and Site of Distension;" <i>Am J Physiol</i> ; March 1996; 270 (3 Pt 1); G470-G475	
		LIN, H. C.; ZHAO, X. T.; and WANG, L. J.; "Intestinal Transit of Fat in Proximal Gut Depends on Accelerating Effect of CCK and Slowing Effect of Opioid Pathway;" <i>Digestive Diseases and Sciences</i> ; September 1996; 41 (9); Abstract Only	
		LIN, H. C.; ZHAO, X. T.; and WANG, L.; "Jejunal Brake: Inhibition of Intestinal Transit by Fat in the Proximal Small Intestine;" <i>Dig. Dis. Sci.</i> ; February 1996; 41 (2); 326-329	
		LIN, H. C.; ZHAO, X. T.; and WANG, L.; "Intestinal Transit Is More Potently Inhibited by Fat in the Distal (Ileal Brake) Than in the Proximal (Jejunal Brake) Gut;" <i>Dig. Dis. Sci.</i> ; January 1997; 42 (1); 19-25; Abstract Only	
		LIN, H. C.; WALSH, J. H.; ZHAO, X. T.; WANG, L. J.; and WONG, H.; "Immunoneutralization of Calcitonin Gene-Related Peptide (CGRP) During Inhibition of Intestinal Transit by Fat;" <i>Gastroenterology</i> ; 1998; 114 (4); A790-; Abstract Only	
		LIN, H. C.; CHEY, W. Y.; TSO, P.; and ZHAO, X. T.; "Release of Cholecystokinin by Proximal Gut Fat Independent of Chylomicron Transport;" <i>Gastroenterology</i> ; 1998; 114 (4); A1159-; Abstract Only	
		LIN, H. C.; WANG, L. J.; and ZHAO, X. T.; "Slowing of Intestinal Transit by Fat in Proximal Gut Depends on Peptide YY;" <i>Neurogastroenterology and Motility</i> ; 1998; 82-; Abstract Only	
		LIN, H. C.; TAYLOR, I. L.; WANG, L. J.; and ZHAO, X. T.; "PYY Release by Fat in the Proximal But Not Distal of Gut Depends on Atropine-Blockable Cholinergic Pathway;" <i>Gastroenterology</i> ; 1998; 114 (4); A1149-; Abstract Only	
		LIN, H. C.; "Intestinal Transit Response to Fat in the Proximal Gut Depends on 5-Hydroxytryptamine;" <i>Gastroenterology</i> ; 1998; 114 (4); A790-; Abstract Only	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/810,020
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
(Use as many sheets as necessary)				Attorney Docket Number	04-11US
Sheet	26	of	41		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIN, H. C.; ZHAO, X. T.; and WANG, L. J.; "Fat-Induced Ileal Brake Depends on Cholecystokinin;" <i>Gastroenterology</i> ; 1998; 114 (4); A790-; Abstract Only	
		LITVAK, D. A.; ISEKI, H.; EVERS, B. M.; GREELEY, G. H., JR.; HELLMICH, M. R.; IWASE, K.; BALASUBRAMANIAM, A.; and TOWNSEND, C. M., JR.; "Characterization of Two Novel Proabsorptive Peptide YY Analogs, BIM-43073D and BIM-43004C;" <i>Dig. Dis. Sci.</i> ; March 1999; 44 (3); 643-648; Abstract Only	
		LIU, C. D.; ALOIA, T.; ADRIAN, T. E.; NEWTON, T. R.; BILCHIK, A. J.; ZINNER, M. J.; ASHLEY, S. W.; and MCFADDEN, D. W.; "Peptide YY: a Potential Proabsorptive Hormone for the Treatment of Malabsorptive Disorders;" <i>Am Surg.</i> ; March 1996; 62 (3); 232-236; Abstract Only	
		LIU, C. D.; NEWTON, T. R.; ZINNER, M. J.; ASHLEY, S. W.; and MCFADDEN, D. W.; "Intraluminal Peptide YY Induces Colonic Absorption in Vivo;" <i>Dis. Colon Rectum</i> ; April 1997; 40 (4); 478-482; Abstract Only	
		LIU, M.; SHEN, L.; and TSO, P.; "The Role of Enterostatin and Apolipoprotein AIV on the Control of Food Intake;" <i>Neuropeptides</i> ; October 1999; 33 (5); 425-433; Abstract Only	
		LUGERING, N.; KUCHARZIK, T.; STOLL, R.; and DOMSCHKE, W.; "Current Concept of the Role of Monocytes/Macrophages in Inflammatory Bowel Disease—Balance of Proinflammatory and Immunosuppressive Mediators;" <i>Ital. J Gastroenterol. Hepatol.</i> ; June 1998; 30 (3); 338-344; Abstract Only	
		LUIKING, Y. C.; VAN DER REIJDEN, A. C.; VAN BERGE HENEGOUWEN, G. P.; and AKKERMANS, L. M.; "Migrating Motor Complex Cycle Duration Is Determined by Gastric or Duodenal Origin of Phase III;" <i>Am J Physiol</i> ; December 1998; 275 (6 Pt 1); G1246-G1251; Abstract Only	
		MACDERMOTT, R. P.; "Alterations of the Mucosal Immune System in Inflammatory Bowel Disease;" <i>J Gastroenterol.</i> ; December 1996; 31 (6); 907-916	
		MACINTOSH, C. G.; ANDREWS, J. M.; JONES, K. L.; WISHART, J. M.; MORRIS, H. A.; JANSEN, J. B.; MORLEY, J. E.; HOROWITZ, M.; and CHAPMAN, I. M.; "Effects of Age on Concentrations of Plasma Cholecystokinin, Glucagon-Like Peptide 1, and Peptide YY and Their Relation to Appetite and Pyloric Motility;" <i>Am J Clin Nutr.</i> ; May 1999; 69 (5); 999-1006; Abstract Only	
		MACK, D. R.; DHAWAN, A.; KAUFMAN, S. S.; LANGNAS, A. N.; and SEEMAYER, T. A.; "Small Bowel Bacterial Overgrowth As a Cause of Chronic Diarrhea After Liver Transplantation in Children;" <i>Liver Transpl. Surg.</i> ; March 1998; 4 (2); 166-169; Abstract Only	
		MAIDA, V. and HOWLETT, G. J.; "Effects of Cigarette Smoking and Dietary Lipids on Rat Lipoprotein Metabolism;" <i>Atherosclerosis</i> ; January 1990; 80 (3); 209-216	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	27	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MAINI, R. N.; "A Perspective on Anti-Cytokine and Anti-T Cell-Directed Therapies in Rheumatoid Arthritis;" <i>Clin Exp. Rheumatol.</i> ; September 1995; 13 Suppl 12 S35-S40; Abstract Only	
		MANNON, P. J.; KANUNGO, A.; MANNON, R. B.; and LUDWIG, K. A.; "Peptide YY/Neuropeptide Y Y1 Receptor Expression in the Epithelium and Mucosal Nerves of the Human Colon;" <i>Regul. Pept.</i> ; August 1999; 83 (1); 11-19; Abstract Only	
		MARLIN, R. G.; ANCHEL, H.; GIBSON, J. C.; GOLDBERG, W. M.; and SWINTON, M.; "An Evaluation of Multidisciplinary Intervention for Chronic Fatigue Syndrome With Long-Term Follow-Up, and a Comparison With Untreated Controls;" <i>Am J Med.</i> ; September 1998; 105 (3A); 110S-114S	
		MASTROPAOLO, G. and REES, W. D.; "Evaluation of the Hydrogen Breath Test in Man: Definition and Elimination of the Early Hydrogen Peak;" <i>Gut</i> ; June 1987; 28 (6); 721-725; Abstract Only	
		MATSUKAWA, A.; YOSHIMURA, T.; MIYAMOTO, K.; OHKAWARA, S.; and YOSHINAGA, M.; "Analysis of the Inflammatory Cytokine Network Among TNF Alpha, IL-1 Beta, IL-1 Receptor Antagonist, and IL-8 in LPS-Induced Rabbit Arthritis;" <i>Lab Invest</i> ; May 1997; 76 (5); 629-638; Abstract Only	
		MATSUKAWA, A. and YOSHINAGA, M.; "Sequential Generation of Cytokines During the Initiative Phase of Inflammation, With Reference to Neutrophils;" <i>Inflamm. Res.</i> ; October 1998; 47 Suppl 3 S137-S144; Abstract Only	
		MAWE, G. M.; BRANCHEK, T. A.; and GERSHON, M. D.; "Peripheral Neural Serotonin Receptors: Identification and Characterization With Specific Antagonists and Agonists;" <i>Proc. Natl. Acad. Sci. U. S. A.</i> ; December 1986; 83 (24); 9799-9803; Abstract Only	
		MCCOLL, K. E.; MURRAY, L. S.; GILLEN, D.; WALKER, A.; WIRZ, A.; FLETCHER, J.; MOWAT, C.; HENRY, E.; KELMAN, A.; and DICKSON, A.; "Randomised Trial of Endoscopy With Testing for Helicobacter Pylori Compared With Non-Invasive H Pylori Testing Alone in the Management of Dyspepsia;" <i>BMJ</i> ; April 2002; 324 (7344); 999-1002	
		MCGILL, H. C., JR.; "Potential Mechanisms for the Augmentation of Atherosclerosis and Atherosclerotic Disease by Cigarette Smoking;" <i>Prev. Med.</i> ; May 1979; 8 (3); 390-403	
		MCHUGH, P. R. and MORAN, T. H.; "The Stomach, Cholecystokinin, and Satiety;" <i>Fed. Proc.</i> ; April 1986; 45 (5); 1384-1390; Abstract Only	
		MCKEOWN, L. A.; "Breath Test Helps Sniff Out Irritable Bowel Syndrome: Majority of Sufferers May Have Treatable Bacterial Infections;" <i>WebMD Medical News</i> ; December 2000	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	28	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MCVAY, L. D.; LI, B.; BIANCANIELLO, R.; CREIGHTON, M. A.; BACHWICH, D.; LICHTENSTEIN, G.; ROMBEAU, J. L.; and CARDING, S. R.; "Changes in Human Mucosal Gamma Delta T Cell Repertoire and Function Associated With the Disease Process in Inflammatory Bowel Disease;" <i>Mol. Med.</i> ; March 1997; 3 (3); 183-203; Abstract Only	
		MEISSNER, W.; SCHMIDT, U.; HARTMANN, M.; KATH, R.; and REINHART, K.; "Oral Naloxone Reverses Opioid-Associated Constipation;" <i>Pain</i> ; January 2000; 84 (1); 105-109; Abstract Only	
		MISHKIN, D. and MISHKIN, S.; "Re: Pimentel Et Al.-Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome;" <i>Am J Gastroenterol.</i> ; August 2001; 96 (8); 2505-2506	
		MJOS, O. D.; FAERGEMAN, O.; HAMILTON, R. L.; and HAVEL, R. J.; "Characterization of Remnants Produced During the Metabolism of Triglyceride-Rich Lipoproteins of Blood Plasma and Intestinal Lymph in the Rat;" <i>J Clin Invest</i> ; September 1975; 56 (3); 603-615	
		MORAN, T. H. and MCHUGH, P. R.; "Cholecystokinin Suppresses Food Intake by Inhibiting Gastric Emptying;" <i>Am J Physiol</i> ; May 1982; 242 (5); R491-R497	
		MORISSE, J.P.; "Effect of a Fructo-Oglio-Saccharides Compound in Rabbits Experimentally Infected with E.Coli;" <i>Journal of Applied Rabbit Research</i> ; 1995; 15, 1137-1143	
		MULLER, S.; LORY, J.; CORAZZA, N.; GRIFFITHS, G. M.; Z'GRAGGEN, K.; MAZZUCHELLI, L.; KAPPELER, A.; and MUELLER, C.; "Activated CD4+ and CD8+ Cytotoxic Cells Are Present in Increased Numbers in the Intestinal Mucosa From Patients With Active Inflammatory Bowel Disease;" <i>Am J Pathol.</i> ; January 1998; 152 (1); 261-268; Abstract Only	
		MURANISHI, S.; TOKUNAGA, Y.; TANIGUCHI, K.; and SEZAKI, H.; "Potential Absorption of Heparin From the Small Intestine and the Large Intestine in the Presence of Monoolein Mixed Micelles;" <i>Chem. Pharm. Bull. (Tokyo)</i> ; May 1977; 25 (5); 1159-1161	
		MURATA, Y.; ISHIGURO, Y.; ITOH, J.; MUNAKATA, A.; and YOSHIDA, Y.; "The Role of Proinflammatory and Immunoregulatory Cytokines in the Pathogenesis of Ulcerative Colitis;" <i>J Gastroenterol.</i> ; November 1995; 30 Suppl 8 56-60; Abstract Only	
		MURPHY, B. V.; ION, F.; and WINSTANLEY, J. R.; "Intestinal Pseudo-Obstruction Associated With Oral Morphine;" <i>Eur J Anaesthesiol</i> ; May 1998; 15 (3); 370-371; Abstract Only	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 29 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MURPHY, K.; "Adults With Attention Deficit Hyperactivity Disorder: Assessment and Treatment Considerations;" <i>Semin. Speech Lang</i> ; August 1996; 17 (3); 245-253; Abstract Only	
		NAIDU, A. S.; BIDLACK, W. R.; and CLEMENS, R. A.; "Probiotic Spectra of Lactic Acid Bacteria (LAB);" <i>Crit Rev. Food Sci. Nutr.</i> ; January 1999; 39 (1); 13-126; Abstract Only	
		NASSIF, A.; LONGO, W. E.; MAZUSKI, J. E.; VERNAVA, A. M.; and KAMINSKI, D. L.; "Role of Cytokines and Platelet-Activating Factor in Inflammatory Bowel Disease. Implications for Therapy;" <i>Dis. Colon Rectum</i> ; February 1996; 39 (2); 217-223; Abstract Only	
		NATELSON, B. H.; LAMANCA, J. J.; DENNY, T. N.; VLADUTIU, A.; OLESKE, J.; HILL, N.; BERGEN, M. T.; KORN, L.; and HAY, J.; "Immunologic Parameters in Chronic Fatigue Syndrome, Major Depression, and Multiple Sclerosis;" <i>Am J Med.</i> ; September 1998; 105 (3A); 43S-49S	
		NAVEILHAN, P.; HASSANI, H.; CANALS, J. M.; EKSTRAND, A. J.; LAREFALK, A.; CHHAJLANI, V.; ARENAS, E.; GEDDA, K.; SVENSSON, L.; THOREN, P.; and ERNFORS, P.; "Normal Feeding Behavior, Body Weight and Leptin Response Require the Neuropeptide Y Y2 Receptor 1;" <i>Nat. Med.</i> ; October 1999; 5 (10); 1188-1193; Abstract Only	
		NIELSEN, O. H.; RUDIGER, N.; GAUSTADNES, M.; and HORN, T.; "Intestinal Interleukin-8 Concentration and Gene Expression in Inflammatory Bowel Disease;" <i>Scand. J Gastroenterol.</i> ; October 1997; 32 (10); 1028-1034; Abstract Only	
		NIESSNER, M. and VOLK, B. A.; "Altered Th1/Th2 Cytokine Profiles in the Intestinal Mucosa of Patients With Inflammatory Bowel Disease As Assessed by Quantitative Reverse Transcribed Polymerase Chain Reaction (RT-PCR);" <i>Clin Exp. Immunol.</i> ; September 1995; 101 (3); 428-435; Abstract Only	
		NIEUWENHUIJS, V. B.; LUIKING, Y. C.; VERHEEM, A.; VANBERGE-HENEGOUWEN, G. P.; GOOSZEN, H. G.; and AKKERMANS, L. M.; "Disrupted Bile Flow Affects Interdigestive Small Bowel Motility in Rats;" <i>Surgery</i> ; September 1997; 122 (3); 600-608; Abstract Only	
		NIEUWENHUIJS, V. B.; VERHEEM, A.; VAN DUIJVENBODE-BEUMER, H.; VISSER, M. R.; VERHOEF, J.; GOOSZEN, H. G.; and AKKERMANS, L. M.; "The Role of Interdigestive Small Bowel Motility in the Regulation of Gut Microflora, Bacterial Overgrowth, and Bacterial Translocation in Rats;" <i>Ann. Surg.</i> ; August 1998; 228 (2); 188-193; Abstract Only	
		NIEUWENHUIJS, V. B.; VAN DUIJVENBODE-BEUMER, H.; VERHEEM, A.; VISSER, M. R.; VERHOEF, J.; GOOSZEN, H. G.; and AKKERMANS, L. M.; "The Effects of ABT-229 and Octreotide on Interdigestive Small Bowel Motility, Bacterial Overgrowth and Bacterial Translocation in Rats;" <i>Eur. J Clin Invest</i> ; January 1999; 29 (1); 33-40; Abstract Only	
		NOOR, N.; SMALL, P. K.; LOUDON, M. A.; HAU, C.; and CAMPBELL, F. C.; "Effects of Cisapride on Symptoms and Postcibal Small-Bowel Motor Function in Patients With Irritable Bowel Syndrome;" <i>Scand. J Gastroenterol.</i> ; June 1998; 33 (6); 605-611	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	30	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		O'BRIEN, J. D.; THOMPSON, D. G.; MCINTYRE, A.; BURNHAM, W. R.; and WALKER, E.; "Effect of Codeine and Loperamide on Upper Intestinal Transit and Absorption in Normal Subjects and Patients With Postvagotomy Diarrhoea;" <i>Gut</i> ; March 1988; 29 (3); 312-318	
		OHTANI, N.; SASAKI, I.; NAITO, H.; TSUCHIYA, T.; TAKAHASHI, M.; SHIBATA, C.; and MATSUNO, S.; "Mediators For Ileal Brake Differ Between the Stomach and Small Intestine in Conscious Dogs;" <i>Gastroenterology</i> ; 1995; 108 (4 Supp.) Abst. 660	
		ORMSBEE, H. S., III and FONDACARO, J. D.; "Action of Serotonin on the Gastrointestinal Tract;" <i>Proc. Soc. Exp. Biol. Med.</i> ; March 1985; 178 (3); 333-338; Abstract Only	
		PANJA, A.; GOLDBERG, S.; ECKMANN, L.; KRISHEN, P.; and MAYER, L.; "The Regulation and Functional Consequence of Proinflammatory Cytokine Binding on Human Intestinal Epithelial Cells;" <i>J Immunol.</i> ; October 1998; 161 (7); 3675-3684	
		PAPPAS, T. N.; MELENDEZ, R. L.; and DEBAS, H. T.; "Gastric Distension Is a Physiologic Satiety Signal in the Dog;" <i>Dig. Dis. Sci.</i> ; October 1989; 34 (10); 1489-1493; Abstract Only	
		PARKES, M.; SATSANGI, J.; and JEWELL, D.; "Contribution of the IL-2 and IL-10 Genes to Inflammatory Bowel Disease (IBD) Susceptibility;" <i>Clin Exp. Immunol.</i> ; July 1998; 113 (1); 28-32; Abstract Only	
		PETERSON, R. L.; WANG, L.; ALBERT, L.; KEITH, J. C., JR.; and DORNER, A. J.; "Molecular Effects of Recombinant Human Interleukin-11 in the HLA-B27 Rat Model of Inflammatory Bowel Disease;" <i>Lab Invest</i> ; December 1998; 78 (12); 1503-1512; Abstract Only	
		PHILLIPS, R. J. and POWLEY, T. L.; "Gastric Volume Rather Than Nutrient Content Inhibits Food Intake;" <i>Am J Physiol</i> ; September 1996; 271 (3 Pt 2); R766-R769; Abstract Only	
		PIMENTEL, M.; CHOW, E. J.; and LIN, H. C.; "Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome. a Double-Blind, Randomized, Placebo-Controlled Study;" <i>Am J Gastroenterol.</i> ; February 2003; 98 (2); 412-419	
		PIMENTEL, M.; MAYER, A. G.; PARK, S.; CHOW, E. J.; HASAN, A.; and KONG, Y.; "Methane Production During Lactulose Breath Test Is Associated With Gastrointestinal Disease Presentation;" <i>Dig. Dis. Sci.</i> ; January 2003; 48 (1); 86-92	
		PIMENTEL, M.; CONSTANTINO, T.; KONG, Y.; BAJWA, M.; REZAEI, A.; and PARK, S.; "A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test;" <i>Dig. Dis. Sci.</i> ; January 2004; 49 (1); 73-77	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 31 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PIMENTEL, M.; WALLACE, D.; HALLEGUA, D.; CHOW, E.; KONG, Y.; PARK, S.; and LIN, H. C.; "A Link Between Irritable Bowel Syndrome and Fibromyalgia May Be Related to Findings on Lactulose Breath Testing;" <i>Ann. Rheum. Dis.</i> ; April 2004; 63 (4); 450-452	
		PIRONI, L.; STANGHELLINI, V.; MIGLIOLI, M.; CORINALDESI, R.; DE, GIORGIO R.; RUGGERI, E.; TOSETTI, C.; POGGIOLI, G.; MORSELLI LABATE, A. M.; MONETTI, N.; and .; "Fat-Induced Ileal Brake in Humans: a Dose-Dependent Phenomenon Correlated to the Plasma Levels of Peptide YY;" <i>Gastroenterology</i> ; September 1993; 105 (3); 733-739	
		POOLE, S.; LORENZETTI, B. B.; CUNHA, J. M.; CUNHA, F. Q.; and FERREIRA, S. H.; "Bradykinin B1 and B2 Receptors, Tumour Necrosis Factor Alpha and Inflammatory Hyperalgesia;" <i>Br. J Pharmacol.</i> ; February 1999; 126 (3); 649-656; Abstract Only	
		PRANTERA, C.; ZANNONI, F.; SCRIBANO, M. L.; BERTO, E.; ANDREOLI, A.; KOHN, A.; and LUZI, C.; "An Antibiotic Regimen for the Treatment of Active Crohn's Disease: a Randomized, Controlled Clinical Trial of Metronidazole Plus Ciprofloxacin;" <i>Am J Gastroenterol.</i> ; February 1996; 91 (2); 328-332	
		PROPST, A.; PROPST, T.; HEROLD, M.; VOGEL, W.; and JUDMAIER, G.; "Interleukin-1 Receptor Antagonist in Differential Diagnosis of Inflammatory Bowel Diseases;" <i>Eur. J Gastroenterol. Hepatol.</i> ; November 1995; 7 (11); 1031-1036; Abstract Only	
		QUINTON, J. F.; SENDID, B.; REUMAUX, D.; DUTHILLEUL, P.; CORTOT, A.; GRANDBASTIEN, B.; CHARRIER, G.; TARGAN, S. R.; COLOMBEL, J. F.; and POULAIN, D.; "Anti-Saccharomyces Cerevisiae Mannan Antibodies Combined With Antineutrophil Cytoplasmic Autoantibodies in Inflammatory Bowel Disease: Prevalence and Diagnostic Role;" <i>Gut</i> ; June 1998; 42 (6): 788-791	
		RADFORD-SMITH, G. and JEWELL, D. P.; "Cytokines and Inflammatory Bowel Disease;" <i>Baillieres Clin Gastroenterol.</i> ; March 1996; 10 (1); 151-164; Abstract Only	
		READ, N. W.; MCFARLANE, A.; KINSMAN, R. I.; BATES, T. E.; BLACKHALL, N. W.; FARRAR, G. B.; HALL, J. C.; MOSS, G.; MORRIS, A. P.; O'NEILL, B.; and .; "Effect of Infusion of Nutrient Solutions into the Ileum on Gastrointestinal Transit and Plasma Levels of Neurotensin and Enteroglucagon;" <i>Gastroenterology</i> ; February 1984; 86 (2); 274-280	
		REASBECK, P. G. and VAN RIJ, A. M.; "The Effect of Somatostatin on Dumping After Gastric Surgery: a Preliminary Report;" <i>Surgery</i> ; April 1986; 99 (4); 462-468	
		REDGRAVE, T. G. and CARLSON, L. A.; "Changes in Plasma Very Low Density and Low Density Lipoprotein Content, Composition, and Size After a Fatty Meal in Normo- and Hypertriglyceridemic Man;" <i>J Lipid Res.</i> ; February 1979; 20 (2); 217-229	
		REIMUND, J. M.; ALLISON, A. C.; MULLER, C. D.; DUMONT, S.; KENNEY, J. S.; BAUMANN, R.; DUCLOS, B.; and POINDRON, P.; "Antioxidants Inhibit the in Vitro Production of Inflammatory Cytokines in Crohn's Disease and Ulcerative Colitis;" <i>Eur. J Clin Invest</i> ; February 1998; 28 (2); 145-150; Abstract Only	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

32

of

41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RHODES, J. M.; MIDDLETON, P.; and JEWELL, D. P.; "The Lactulose Hydrogen Breath Test As a Diagnostic Test for Small-Bowel Bacterial Overgrowth," <i>Scand. J Gastroenterol.</i> ; 1979; 14 (3); 333-336; Abstract Only	
		RIORDAN, S. M.; MCIVER, C. J.; WALKER, B. M.; DUNCOMBE, V. M.; BOLIN, T. D.; and THOMAS, M. C.; "The Lactulose Breath Hydrogen Test and Small Intestinal Bacterial Overgrowth," <i>Am J Gastroenterol.</i> ; September 1996; 91 (9); 1795-1803; Abstract Only	
		RIORDAN, S. M.; MCIVER, C. J.; WAKEFIELD, D.; BOLIN, T. D.; DUNCOMBE, V. M.; and THOMAS, M. C.; "Small Intestinal Bacterial Overgrowth in the Symptomatic Elderly," <i>Am J Gastroenterol.</i> ; January 1997; 92 (1); 47-51	
		ROGLER, G. and ANDUS, T.; "Cytokines in Inflammatory Bowel Disease," <i>World J Surg.</i> ; April 1998; 22 (4); 382-389; Abstract Only	
		ROLAK, L. A.; "The Diagnosis of Multiple Sclerosis," <i>Neurol. Clin.</i> ; February 1996; 14 (1); 27-43	
		ROMBEAU, J. L. and ROLANDELLI, R. H.; "Enteral and Parenteral Nutrition in Patients With Enteric Fistulas and Short Bowel Syndrome," <i>Surg. Clin North Am</i> ; June 1987; 67 (3); 551-571	
		ROWE, P. C. and CALKINS, H.; "Neurally Mediated Hypotension and Chronic Fatigue Syndrome," <i>Am J Med.</i> ; September 1998; 105 (3A); 15S-21S	
		RUEMMELE, F. M.; TARGAN, S. R.; LEVY, G.; DUBINSKY, M.; BRAUN, J.; and SEIDMAN, E. G.; "Diagnostic Accuracy of Serological Assays in Pediatric Inflammatory Bowel Disease," <i>Gastroenterology</i> ; October 1998; 115 (4); 822-829	
		RUSELER-VAN EMBDEN, J. G. and BOTH-PATOIR, H. C.; "Anaerobic Gram-Negative Faecal Flora in Patients With Crohn's Disease and Healthy Subjects," <i>Antonie Van Leeuwenhoek</i> ; June 1983; 49 (2); 125-132; Abstract Only	
		RUTGEERTS, P.; GHOOS, Y.; VANTRAPPEN, G.; and EYSSEN, H.; "Small Bowel Bacterial Overgrowth, Ileal Dysfunction and Stool Fat Excretion in Patients With Unoperated Crohn's Disease," <i>Gastroenterology</i> ; 1979; 76 (5, part 2); 1232-	
		SAHU, A.; SNINSKY, C. A.; and KALRA, S. P.; "Evidence That Hypothalamic Neuropeptide Y Gene Expression and NPY Levels in the Paraventricular Nucleus Increase Before the Onset of Hyperphagia in Experimental Diabetes," <i>Brain Res.</i> ; May 1997; 755 (2); 339-342; Abstract Only	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	33	of	41	Attorney Docket Number	04-011US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SAHU, A.; "Evidence Suggesting That Galanin (GAL), Melanin-Concentrating Hormone (MCH), Neurotensin (NT), Proopiomelanocortin (POMC) and Neuropeptide Y (NPY) Are Targets of Leptin Signaling in the Hypothalamus;" <i>Endocrinology</i> ; February 1998; 139 (2); 795-798; Abstract Only	
		SAIKI, T.; MITSUYAMA, K.; TOYONAGA, A.; ISHIDA, H.; and TANIKAWA, K.; "Detection of Pro- and Anti-Inflammatory Cytokines in Stools of Patients With Inflammatory Bowel Disease;" <i>Scand. J Gastroenterol.</i> ; June 1998; 33 (6); 616-622; Abstract Only	
		SAKAI, T.; KUSUGAMI, K.; NISHIMURA, H.; ANDO, T.; YAMAGUCHI, T.; OHSUGA, M.; INA, K.; ENOMOTO, A.; KIMURA, Y.; and YOSHIKAI, Y.; "Interleukin 15 Activity in the Rectal Mucosa of Inflammatory Bowel Disease;" <i>Gastroenterology</i> ; June 1998; 114 (6); 1237-1243; Abstract Only	
		SANGER, G. J.; "5-Hydroxytryptamine and Functional Bowel Disorders;" <i>Neurogastroenterol. Motil.</i> ; December 1996; 8 (4); 319-331; Abstract Only	
		SANGER, G. J.; "Hypersensitivity and Hyperreactivity in the Irritable Bowel Syndrome: An Opportunity for Drug Discovery;" <i>Dig. Dis.</i> ; 1999; 17 (2); 90-99; Abstract Only	
		SANGER, G. J.; YOSHIDA, M.; YAHYAH, M.; and KITAZUMI, K.; "Increased Defecation During Stress or After 5-Hydroxytryptophan: Selective Inhibition by the 5-HT(4) Receptor Antagonist, SB-207266;" <i>Br. J Pharmacol.</i> ; June 2000; 130 (3); 706-712; Abstract Only	
		SANTOS, F. A. and RAO, V. S.; "Quinine-Induced Inhibition of Gastrointestinal Transit in Mice: Possible Involvement of Endogenous Opioids;" <i>Eur. J Pharmacol.</i> ; January 1999; 364 (2-3); 193-197; Abstract Only	
		SARTOR, R. B.; "Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases;" <i>Am J Gastroenterol.</i> ; December 1997; 92 (12 Suppl); 5S-11S	
		SAUNDERS, D. R. and SILLERY, J. K.; "Absorption of Triglyceride by Human Small Intestine: Dose-Response Relationships;" <i>Am J Clin Nutr.</i> ; October 1988; 48 (4); 988-991	
		SCHEMANN, M. and EHRLEIN, H. J.; "The Utility of Cellulose Meals for Studies on Gastrointestinal Motility in Dogs;" <i>Digestion</i> ; 1982; 25 (3); 194-196	
		SCHEMANN, M. and EHRLEIN, H. J.; "Postprandial Patterns of Canine Jejunal Motility and Transit of Luminal Content;" <i>Gastroenterology</i> ; April 1986; 90 (4); 991-1000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 34 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SCHMIDT, T.; HACKELSBERGER, N.; WIDMER, R.; MEISEL, C.; PFEIFFER, A.; and KAESS, H.; "Ambulatory 24-Hour Jejunal Motility in Diarrhea-Predominant Irritable Bowel Syndrome;" <i>Scand. J Gastroenterol.</i> ; June 1996; 31 (6); 581-589; Abstract Only	
		SCHNEIDER, A.; NOVIS, B.; CHEN, V.; and LEICHTMAN, G.; "Value of the 14C-D-Xylose Breath Test in Patients With Intestinal Bacterial Overgrowth;" <i>Digestion</i> ; 1985; 32 (2); 86-91	
		SCHREIBER, S.; HEINIG, T.; THIELE, H. G.; and RAEDLER, A.; "Immunoregulatory Role of Interleukin 10 in Patients With Inflammatory Bowel Disease;" <i>Gastroenterology</i> ; May 1995; 108 (5); 1434-1444; Abstract Only	
		SCHREIBER, S.; HEINIG, T.; PANZER, U.; REINKING, R.; BOUCHARD, A.; STAHL, P. D.; and RAEDLER, A.; "Impaired Response of Activated Mononuclear Phagocytes to Interleukin 4 in Inflammatory Bowel Disease;" <i>Gastroenterology</i> ; January 1995; 108 (1); 21-33; Abstract Only	
		SCHREIBER, S.; "Experimental Immunomodulatory Therapy of Inflammatory Bowel Disease;" <i>Neth. J Med.</i> ; December 1998; 53 (6); S24-S31; Abstract Only	
		SHARPE, M.; "Cognitive Behavior Therapy for Chronic Fatigue Syndrome: Efficacy and Implications;" <i>Am J Med.</i> ; September 1998; 105 (3A); 104S-109S	
		SHIGEMATSU, S.; "Therapeutic Potential of Interleukin-1 Receptor Antagonist in Inflammatory Bowel Disease;" <i>Kurume Med. J.</i> ; 1998; 45 (2); 175-179; Abstract Only	
		SHIRACHI, A.; "Therapeutic Implications of Interleukin-10 in Inflammatory Bowel Disease;" <i>Kurume Med. J.</i> ; 1998; 45 (1); 63-67; Abstract Only	
		SIEGLE, M. L.; SCHMID, H. R.; and EHRLEIN, H. J.; "Effects of Ileal Infusions of Nutrients on Motor Patterns of Canine Small Intestine;" <i>Am J Physiol</i> ; July 1990; 259 (1 Pt 1); G78-G85	
		SILBERBAUER, C. J.; SURINA-BAUMGARTNER, D. M.; ARNOLD, M.; and LANGHANS, W.; "Prandial Lactate Infusion Inhibits Spontaneous Feeding in Rats;" <i>Am J Physiol Regul. Integr. Comp Physiol</i> ; March 2000; 278 (3); R646-R653; Abstract Only	
		SIMANSKY, K. J.; JAKUBOW, J.; SISK, F. C.; VAIDYA, A. H.; and EBERLE-WANG, K.; "Peripheral Serotonin Is an Incomplete Signal for Eliciting Satiety in Sham-Feeding Rats;" <i>Pharmacol. Biochem. Behav.</i> ; November 1992; 43 (3); 847-854; Abstract Only	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 35 of 41

Complete if Known

Application Number	10/810,020
Filing Date	3/26/2004
First Named Inventor	Lin
Art Unit	1645
Examiner Name	Swartz, Rodney P.
Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SIMPSON, J. W.; "Diet and Large Intestinal Disease in Dogs and Cats;" <i>Journal of Nutrition</i> ; December 1996; 128 (12 Suppl.); 2717S-2722S	
		SMITH, B. K.; YORK, D. A.; and BRAY, G. A.; "Activation of Hypothalamic Serotonin Receptors Reduced Intake of Dietary Fat and Protein but Not Carbohydrate;" <i>Am J Physiol</i> ; September 1999; 277 (3 Pt 2); R802-R811; Abstract Only	
		SODERHOLM, J. D.; PETERSON, K. H.; OLAISON, G.; FRANZEN, L. E.; WESTROM, B.; MAGNUSSON, K. E.; and SJODAHL, R.; "Epithelial Permeability to Proteins in the Noninflamed Ileum of Crohn's Disease?;" <i>Gastroenterology</i> ; July 1999; 117 (1); 65-72	
		SOLL, A. H.; "Medical Treatment of Peptic Ulcer Disease;" <i>JAMA</i> ; February 28, 1996; 275(8)	
		SOLL, A. H.; "Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology;" <i>JAMA</i> ; February 28, 1996; 257(8); 622-629	
		SOPER, N. J.; CHAPMAN, N. J.; KELLY, K. A.; BROWN, M. L.; PHILLIPS, S. F.; and GO, V. L.; "The 'Ileal Brake' After Ileal Pouch-Anal Anastomosis;" <i>Gastroenterology</i> ; January 1990; 98 (1); 111-116	
		SPANHAAK, S.; HAVENAAR, R.; and SCHAAFSMA, G.; "The Effect of Consumption of Milk Fermented by Lactobacillus Casei Strain Shirota on the Intestinal Microflora and Immune Parameters in Humans;" <i>Eur. J Clin Nutr.</i> ; December 1998; 52 (12); 899-907; Abstract Only	
		SPERBER, A. D.; CARMEL, S.; ATZMON, Y.; WEISBERG, I.; SHALIT, Y.; NEUMANN, L.; FICH, A.; FRIGER, M.; and BUSKILA, D.; "Use of the Functional Bowel Disorder Severity Index (FBDSI) in a Study of Patients With the Irritable Bowel Syndrome and Fibromyalgia;" <i>Am J Gastroenterol.</i> ; April 2000; 95 (4); 995-998	
		SPILLER, R. C.; TROTMAN, I. F.; HIGGINS, B. E.; GHATEI, M. A.; GRIMBLE, G. K.; LEE, Y. C.; BLOOM, S. R.; MISIEWICZ, J. J.; and SILK, D. B.; "The Ileal Brake—Inhibition of Jejunal Motility After Ileal Fat Perfusion in Man;" <i>Gut</i> ; April 1984; 25 (4); 365-374	
		SPILLER, R. C.; TROTMAN, I. F.; ADRIAN, T. E.; BLOOM, S. R.; MISIEWICZ, J. J.; and SILK, D. B.; "Further Characterisation of the 'Ileal Brake' Reflex in Man—Effect of Ileal Infusion of Partial Digests of Fat, Protein, and Starch on Jejunal Motility and Release of Neurotensin, Enteroglucagon, and Peptide YY;" <i>Gut</i> ; August 1988; 29 (8); 1042-1051	
		STACK, W. A.; MANN, S. D.; ROY, A. J.; HEATH, P.; SOPWITH, M.; FREEMAN, J.; HOLMES, G.; LONG, R.; FORBES, A.; and KAMM, M. A.; "Randomised Controlled Trial of CDP571 Antibody to Tumour Necrosis Factor-Alpha in Crohn's Disease;" <i>Lancet</i> ; February 1997; 349 (9051); 521-524; Abstract Only	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	36	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		STARHA, L. and CHALABALA, M.; "[Oral Long-Acting Drugs. 8. Effects of Palmitic and Lauric Acid and Their Glycerine Esters on the Slowing of the Drug Release];" <i>Cesk. Farm.</i> ; September 1972; 21 (7); 311-314	
		STEADMAN, C. J.; TALLEY, N. J.; PHILLIPS, S. F.; and ZINSMEISTER, A. R.; "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron As Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: a Pilot Study;" <i>Mayo Clin Proc.</i> ; August 1992; 67 (8); 732-738; Abstract Only	
		STEELE, L.; DOBBINS, J. G.; FUKUDA, K.; REYES, M.; RANDALL, B.; KOPPELMAN, M.; and REEVES, W. C.; "The Epidemiology of Chronic Fatigue in San Francisco;" <i>Am J Med.</i> ; September 1998; 105 (3A); 83S-90S	
		STOTZER, P. O.; BJORNSSON, E. S.; and ABRAHAMSSON, H.; "Interdigestive and Postprandial Motility in Small-Intestinal Bacterial Overgrowth;" <i>Scand. J Gastroenterol.</i> ; September 1996; 31 (9); 875-880; Abstract Only	
		STROCCHI, A.; CORAZZA, G.; ELLIS, C. J.; GASBARRINI, G.; and LEVITT, M. D.; "Detection of Malabsorption of Low Doses of Carbohydrate: Accuracy of Various Breath H ₂ Criteria;" <i>Gastroenterology</i> ; November 1993; 105 (5); 1404-1410; Abstract Only	
		SUMMERS, R. W.; CRAMER, J.; and FLATT, A. J.; "Computerized Analysis of Spike Burst Activity in the Small Intestine;" <i>IEEE Trans. Biomed. Eng.</i> ; May 1982; 29 (5); 309-314	
		SWANINK, C. M.; STOLK-ENGELAAR, V. M.; VAN DER MEER, J. W.; VERCOULEN, J. H.; BLEIJENBERG, G.; FENNIS, J. F.; GALAMA, J. M.; and HOOBKAMP-KORSTANJE, J. A.; "Yersinia Enterocolitica and the Chronic Fatigue Syndrome;" <i>J Infect.</i> ; May 1998; 36 (3); 269-272; Abstract Only	
		SWART, G. R. and VAN DEN BERG, J. W.; "13C Breath Test in Gastroenterological Practice;" <i>Scand. J Gastroenterol. Suppl.</i> ; 1998; 225 13-18; Abstract Only	
		SWINARD and LOWENTHAL; "Emulsifying and Suspending Agents;" 1985; 17 (68); 1296-1300	
		TALLEY, N. J.; "Review Article: 5-Hydroxytryptamine Agonists and Antagonists in the Modulation of Gastrointestinal Motility and Sensation: Clinical Implications;" <i>Aliment. Pharmacol. Ther.</i> ; June 1992; 6 (3); 273-289; Abstract Only	
		TARGAN, S. R.; HANAUER, S. B.; VAN DEVENTER, S. J.; MAYER, L.; PRESENT, D. H.; BRAAKMAN, T.; DEWOODY, K. L.; SCHAIBLE, T. F.; and RUTGEERTS, P. J.; "A Short-Term Study of Chimeric Monoclonal Antibody CA2 to Tumor Necrosis Factor Alpha for Crohn's Disease. Crohn's Disease CA2 Study Group;" <i>N. Engl. J Med.</i> ; October 1997; 337 (15); 1029-1035	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/810,020	
			Filing Date	3/26/2004	
			First Named Inventor	Lin	
			Art Unit	1645	
			Examiner Name	Swartz, Rodney P.	
Sheet	37	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TARGAN, S. R.; "The Utility of ANCA and ASCA in Inflammatory Bowel Disease;" <i>Inflamm. Bowel. Dis.</i> ; February 1999; 5 (1); 61-63	
		TERMAN, M.; LEVINE, S. M.; TERMAN, J. S.; and DOHERTY, S.; "Chronic Fatigue Syndrome and Seasonal Affective Disorder: Comorbidity, Diagnostic Overlap, and Implications for Treatment;" <i>Am J Med.</i> ; September 1998; 105 (3A); 115S-124S	
		TIRELLI, U.; CHIERICHETTI, F.; TAVIO, M.; SIMONELLI, C.; BIANCHIN, G.; ZANCO, P.; and FERLIN, G.; "Brain Positron Emission Tomography (PET) in Chronic Fatigue Syndrome: Preliminary Data;" <i>Am J Med.</i> ; September 1998; 105 (3A); 54S-58S	
		TRIADAFILOPOULOS, G.; SIMMS, R. W.; and GOLDENBERG, D. L.; "Bowel Dysfunction in Fibromyalgia Syndrome;" <i>Dig. Dis. Sci.</i> ; January 1991; 36 (1); 59-64	
		TURTON, M. D.; O'SHEA, D.; GUNN, I.; BEAK, S. A.; EDWARDS, C. M.; MEERAN, K.; CHOI, S. J.; TAYLOR, G. M.; HEATH, M. M.; LAMBERT, P. D.; WILDING, J. P.; SMITH, D. M.; GHATEI, M. A.; HERBERT, J.; and BLOOM, S. R.; "A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding;" <i>Nature</i> ; January 1996; 379 (6560); 69-72; Abstract Only	
		VAN DEN BERG, W. B.; "Joint Inflammation and Cartilage Destruction May Occur Uncoupled;" <i>Springer Semin. Immunopathol.</i> ; 1998; 20 (1-2); 149-164; Abstract Only	
		VAN DIJK, G. and THIELE, T. E.; "Glucagon-Like Peptide-1 (7-36) Amide: a Central Regulator of Satiety and Interceptive Stress;" <i>Neuropeptides</i> ; October 1999; 33 (5); 406-414; Abstract Only	
		VAN DULLEMEN, H. M.; VAN DEVENTER, S. J.; HOMMES, D. W.; BIJL, H. A.; JANSEN, J.; TYTGAT, G. N.; and WOODY, J.; "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (CA2);" <i>Gastroenterology</i> ; July 1995; 109 (1); 129-135; Abstract Only	
		VAN HOGEZAND, R. A. and VERSPAGET, H. W.; "Selective Immunomodulation in Patients With Inflammatory Bowel Disease--Future Therapy or Reality?;" <i>Neth. J Med.</i> ; February 1996; 48 (2); 64-67; Abstract Only	
		VAN HOGEZAND, R. A. and VERSPAGET, H. W.; "The Future Role of Anti-Tumour Necrosis Factor-Alpha Products in the Treatment of Crohn's Disease;" <i>Drugs</i> ; September 1998; 56 (3); 299-305; Abstract Only	
		VANDERHOOF, J. A. and YOUNG, R. J.; "Use of Probiotics in Childhood Gastrointestinal Disorders;" <i>J Pediatr. Gastroenterol. Nutr.</i> ; September 1998; 27 (3); 323-332; Abstract Only	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/810,020
			<i>Filing Date</i>	3/26/2004
			<i>First Named Inventor</i>	Lin
			<i>Art Unit</i>	1645
			<i>Examiner Name</i>	Swartz, Rodney P.
(Use as many sheets as necessary)			<i>Attorney Docket Number</i>	04-11US
Sheet	38	of	41	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VANDERHOOF, J. A.; YOUNG, R. J.; MURRAY, N.; and KAUFMAN, S. S.; "Treatment Strategies for Small Bowel Bacterial Overgrowth in Short Bowel Syndrome," <i>J Pediatr. Gastroenterol. Nutr.</i> ; August 1998; 27 (2); 155-160; Abstract Only	
		VARGA, G.; KORDAS, K.; BURGHARDT, B.; GACSALYI, I.; and SZENASI, G.; "Effect of Deramciclane, a New 5-HT Receptor Antagonist, on Cholecystokinin-Induced Changes in Rat Gastrointestinal Function," <i>Eur. J Pharmacol.</i> ; February 1999; 367 (2-3); 315-323; Abstract Only	
		VARNI, J. W.; RAPOFF, M. A.; WALDRON, S. A.; GRAGG, R. A.; BERNSTEIN, B. H.; and LINDSLEY, C. B.; "Chronic Pain and Emotional Distress in Children and Adolescents," <i>J Dev. Behav. Pediatr.</i> ; June 1996; 17 (3); 154-161; Abstract Only	
		VERKIJK, M.; GIELKENS, H. A.; LAMERS, C. B.; and MASCLÉE, A. A.; "Effect of Gastrin on Antroduodenal Motility: Role of Intraluminal Acidity," <i>Am J Physiol</i> ; November 1998; 275 (5 Pt 1); G1209-G1216	
		VOIGT, J. P.; FINK, H.; and MARSDEN, C. A.; "Evidence for the Involvement of the 5-HT _{1A} Receptor in CCK Induced Satiety in Rats," <i>Naunyn Schmiedeberg's Arch. Pharmacol.</i> ; March 1995; 351 (3); 217-220; Abstract Only	
		VOIGT, J. P.; KIENZLE, F.; SOHR, R.; REX, A.; and FINK, H.; "Feeding and 8-OH-DPAT-Related Release of Serotonin in the Rat Lateral Hypothalamus," <i>Pharmacol. Biochem. Behav.</i> ; January 2000; 65 (1); 183-189; Abstract Only	
		WADE, P. R.; TAMIR, H.; KIRCHGESSNER, A. L.; and GERSHON, M. D.; "Analysis of the Role of 5-HT in the Enteric Nervous System Using Anti-Idiotopic Antibodies to 5-HT Receptors," <i>Am J Physiol</i> ; March 1994; 266 (3 Pt 1); G403-G416; Abstract Only	
		WADE, P. R.; CHEN, J.; JAFFE, B.; KASSEM, I. S.; BLAKELY, R. D.; and GERSHON, M. D.; "Localization and Function of a 5-HT Transporter in Crypt Epithelia of the Gastrointestinal Tract," <i>J Neurosci.</i> ; April 1996; 16 (7); 2352-2364; Abstract Only	
		WARNICK, G. R.; "Enzymatic Methods for Quantification of Lipoprotein Lipids," <i>Methods Enzymol.</i> ; 1986; 129 101-123	
		WAY, LAWRENCE W.; "Current Surgical Diagnosis & Treatment," 1991; 9 1083- Appleton & Lange (Norwalk, Connecticut)	
		Website Reference: Great Smokies Diagnostic Library (May 4, 1999)	
		WECKMANN, A. L. and COCER-VARELA, J.; "Cytokine Inhibitors in Autoimmune Disease," <i>Semin. Arthritis Rheum.</i> ; October 1996; 26 (2); 539-557; Abstract Only	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,020
				Filing Date	3/26/2004
				First Named Inventor	Lin
				Art Unit	1645
				Examiner Name	Swartz, Rodney P.
Sheet	39	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WELCH, I. M.; DAVISON, P. A.; WORLDING, J.; and READ, N. W.; "Effect of Ileal Infusion of Lipid on Jejunal Motor Patterns After a Nutrient and Nonnutrient Meal;" <i>Am J Physiol</i> ; December 1988; 255 (6 Pt 1); G800-G806	
		WELLMANN, W. and SCHMIDT, F. W.; "Intestinal Lavage in the Treatment of Crohn's Disease: A Pilot Study;" <i>Klinische Wochenschrift</i> ; 1982; 60 (7); 371-374	
		WHITEHEAD, W. E.; PALSSON, O.; and JONES, K. R.; "Systematic Review of the Comorbidity of Irritable Bowel Syndrome With Other Disorders: What Are the Causes and Implications?;" <i>Gastroenterology</i> ; April 2002; 122 (4); 1140-1156	
		WHITESIDE, T. L. and FRIBERG, D.; "Natural Killer Cells and Natural Killer Cell Activity in Chronic Fatigue Syndrome;" <i>Am J Med.</i> ; September 1998; 105 (3A); 27S-34S	
		WOLF, B. W.; WHEELER, K. B.; ATAYA, D. G.; and GARLEB, K. A.; "Safety and Tolerance of Lactobacillus Reuteri Supplementation to a Population Infected With the Human Immunodeficiency Virus;" <i>Food Chem. Toxicol.</i> ; December 1998; 36 (12); 1085-1094; Abstract Only	
		WOLF, G.; "Neuropeptides Responding to Leptin;" <i>Nutr. Rev.</i> ; March 1997; 55 (3); 85-88; Abstract Only	
		WOLFE, F.; "Fibromyalgia: the Clinical Syndrome;" <i>Rheum. Dis. Clin North Am</i> ; February 1989; 15 (1); 1-18	
		WOLFE, F.; ROSS, K.; ANDERSON, J.; and RUSSELL, I. J.; "Aspects of Fibromyalgia in the General Population: Sex, Pain Threshold, and Fibromyalgia Symptoms;" <i>J Rheumatol.</i> ; January 1995; 22 (1); 151-156	
		WOO, P.; "Cytokines in Juvenile Chronic Arthritis;" <i>Baillieres Clin Rheumatol.</i> ; May 1998; 12 (2); 219-228; Abstract Only	
		WU, A. L.; CLARK, S. B.; and HOLT, P. R.; "Transmucosal Triglyceride Transport Rates in Proximal and Distal Rat Intestine in Vivo;" <i>J Lipid Res.</i> ; July 1975; 16 (4); 251-257	
		WU, A. L. and BENNETT, CLARK S.; "Resistance of Intestinal Triglyceride Transport Capacity in the Rat to Adaptation to Altered Luminal Environment;" <i>Am J Clin Nutr.</i> ; February 1976; 29 (2); 157-168	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/810,020
		<i>Filing Date</i>	3/26/2004
		<i>First Named Inventor</i>	Lin
		<i>Art Unit</i>	1645
		<i>Examiner Name</i>	Swartz, Rodney P.
(Use as many sheets as necessary)		<i>Attorney Docket Number</i>	04-11US
Sheet	40	of	41

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WU, A. L.; CLARK, S. B.; and HOLT, P. R.; "Composition of Lymph Chylomicrons From Proximal or Distal Rat Small Intestine;" <i>Am J Clin Nutr</i> ; March 1980; 33 (3); 582-589	
		YOUNG, GRAEME P.; "Colorectal Disorders: a Dietary Management Perspective;" <i>Asia Pacific J Clin Nutr</i> ; 2000; 9 (Suppl); S76-S82	
		YUAN, C. S.; FOSS, J. F.; OSINSKI, J.; TOLEDANO, A.; ROIZEN, M. F.; and MOSS, J.; "The Safety and Efficacy of Oral Methylnaltrexone in Preventing Morphine-Induced Delay in Oral-Cecal Transit Time;" <i>Clin Pharmacol. Ther.</i> ; April 1997; 61 (4); 467-475; Abstract Only	
		YUAN, C. S.; FOSS, J. F.; O'CONNOR, M.; OSINSKI, J.; ROIZEN, M. F.; and MOSS, J.; "Effects of Intravenous Methylnaltrexone on Opioid-Induced Gut Motility and Transit Time Changes in Subjects Receiving Chronic Methadone Therapy: a Pilot Study;" <i>Pain</i> ; December 1999; 83 (3); 631-635; Abstract Only	
		YUAN, C. S.; FOSS, J. F.; O'CONNOR, M.; OSINSKI, J.; KARRISON, T.; MOSS, J.; and ROIZEN, M. F.; "Methylnaltrexone for Reversal of Constipation Due to Chronic Methadone Use: a Randomized Controlled Trial;" <i>JAMA</i> ; January 2000; 283 (3); 367-372; Abstract Only	
		ZHOU, X. T.; WANG, L. J.; ELASHOFF, J. D.; and LIN, H. C.; "Fat in Distal Gut Inhibits Intestinal Transit More Potently Than Fat in Proximal Gut;" <i>Gastroenterology</i> ; April 1995; 108 (4); A714; Abstract Only	
		ZILVERSMIT, D. B.; "Chylomicrons;" 1969; (C1); 329-368; Academic (New York, NY)	
		ZILVERSMIT, D. B.; "Atherogenesis: a Postprandial Phenomenon;" <i>Circulation</i> ; September 1979; 60 (3); 473-485	
		ADRIAN, T. E.; FERRI, G. L.; BACARESE-HAMILTON, A. J.; FUESSL, H. S.; POLAK, J. M.; and BLOOM, S. R.; "Human Distribution and Release of a Putative New Gut Hormone, Peptide YY;" <i>Gastroenterology</i> ; November 1985; 89 (5); 1070-1077	
		PIMENTEL, M. et al; "Eradication of Small Intestinal Bacterial Overgrowth Decreases the Gastrointestinal Symptoms in Fibromyalgia;" <i>Gastroenterology</i> ; April 2000; 118 (4 Supl.2 Part 1); AGA pg A413	
		PIMENTEL, M. et al; "Comparison of Peak Breath Hydrogen Production in Patients with Irritable Bowel Syndrome, Chronic Fatigue Syndrome and Fibromyalgia;" <i>Gastroenterology</i> ; April 2000; 118 (4 Supl.2 Part 1); AGA pg A413	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/810,020		
		Filing Date	3/26/2004		
		First Named Inventor	Lin		
		Art Unit	1645		
Examiner Name	Swartz, Rodney P.				
Sheet	41	of	41	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PIMENTEL, M. et al; "Eradication of Small Intestinal Bacterial Decreases Symptoms in Fibromyalgia: A Double Blind Randomized Study," <i>Arthritis & Rheumatism</i> ; November 13-14 1999; 42 (9 Suppl.); S343; Abstract 1632	
		PIMENTEL, M. et al; "Eradication of Small Intestinal Bacterial Overgrowth Decreases Symptoms in Chronic Fatigue Syndrome: A Double Blind, Randomized Study," <i>Gastroenterology</i> ; April 2000; 118 (4 Supl.2 Part 1); AGA pg A414; <i>Arthritis & Rheumatism</i> ; 1999; 42 (9 Suppl.); S343	
		PIMENTEL, M. et al; <i>The American Journal of Gastroenterology</i> ; 2000; 95 (12); 3503-3506	
		PIMENTEL, M. "Small Intestinal Bacterial Overgrowth: A Possible Association with Fibromyalgia," <i>Journal of Musculoskeletal Pain</i> ; 9(3)	
		TATEMOTO, K. and MUTT, V.; "Isolation of Two Novel Candidate Hormones Using a Chemical Method for Finding Naturally Occurring Polypeptides 1," <i>Nature</i> ; June 1980; 285 (5764); 417-418	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.